Biotechnology and Biopharma News

Major General James Gilman, M.D., tapped to lead NIH Clinical Center
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announces the selection of Major General James K. Gilman, M.D.
12/09/16, National Institutes of Health

Compugen’s Cancer Immunotherapy Program Targets TIGIT Immune Checkpoint

TIGIT immune checkpointCompugen has revealed details of its cancer immunotherapy program for TIGIT – internally known as CGEN-15137 – an immune checkpoint that has recently gained attention from the immuno-oncology industry. TIGIT, a T-cell immune-receptor with Ig and ITIM domains, has the potential to inhibit both T-cell and NK-cell activation when bound to its ligand poliovirus receptor (PVR). TIGIT has the ability to […]

The post Compugen’s Cancer Immunotherapy Program Targets TIGIT Immune Checkpoint appeared first on Immuno-Oncology News.


12/09/16, Immuno-Oncology News

TEtools – facilitates big data expression analysis of transposable elements
Over recent decades, substantial efforts have been made to understand the interactions between host genomes and transposable elements (TEs). The impact of TEs on the regulation of host genes is well known, with TEs acting as platforms of regulatory sequences. Nevertheless, due to their repetitive nature it is considerably hard to integrate TE analysis into ...
12/09/16, Transcriptome Research & Industry News

Single-cell barcoding and sequencing using droplet microfluidics
Single-cell RNA sequencing has recently emerged as a powerful tool for mapping cellular heterogeneity in diseased and healthy tissues, yet high-throughput methods are needed for capturing the unbiased diversity of cells. Droplet microfluidics is among the most promising candidates for capturing and processing thousands of individual cells for whole-transcriptome or genomic analysis in a massively ...
12/09/16, Transcriptome Research & Industry News

RNA-Seq Trending in Google Searches

12/09/16, Transcriptome Research & Industry News

Running can reduce joint inflammation, study finds
We all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health. You know; no pain, no gain.
12/09/16, News Medical Life Sciences

Psychiatrist explains how the brain blocks memory to help get through traumatic event
Everyone has done something they probably want to forget—falling face first on the stage at your high school graduation or asking a woman how far along she is only to find out she isn't even pregnant.
12/09/16, News Medical Life Sciences

Proton Partners acquires Blue Phantom2 data acquisition system to support innovative cancer treatment
The first ever Proton Partners International site, specialising in proton beam therapy, has acquired a Blue Phantom2 data acquisition system from IBA to commission its IBA Proteus ONE compact proton therapy machine and Elekta Versa HD linear accelerator.
12/09/16, News Medical Life Sciences

Oral cavity bacterium linked to development and progression of esophageal cancer
A type of bacterium usually found in the human mouth, Fusobacterium nucleatum, has been found to be related to the prognosis of esophageal cancer in Japanese patients by researchers from Kumamoto University, Japan.
12/09/16, News Medical Life Sciences

New research centre aims to study integration of Traditional Chinese Medicine with western medicine
A NEW research centre to study how Traditional Chinese Medicine (TCM) could be used to treat some of the world’s deadliest diseases is being launched in Beijing today.
12/09/16, News Medical Life Sciences

New brain scan could act as diagnostic tool in Parkinson’s
A type of brain scan could act as a diagnostic tool in Parkinson’s according to a new study published in the scientific journal Radiology.
12/09/16, News Medical Life Sciences

New IDT webinar to highlight benefits of using RNP complexes for efficient genome modifications
Integrated DNA Technologies will host an informative webinar entitled ‘Ribonucleoprotein delivery of CRISPR-Cas9 reagents for increased gene editing efficiency’ on December 14, 2016.
12/09/16, News Medical Life Sciences

Moderate exercise may help treat memory impairment in patients with type 2 diabetes
University of Tsukuba-led researchers show that moderate exercise may improve hippocampal memory dysfunction caused by type 2 diabetes and that enhanced transport of lactate to neurons may be the underlying mechanism
12/09/16, News Medical Life Sciences

Jets of plasma used in arc welding may help kill cancer cells and heal wounds
JETS of plasma traditionally used in arc welding could soon be used to kill cancer cells and heal wounds.
12/09/16, News Medical Life Sciences

Defective ribosomes linked to aggressive form of multiple myeloma
20 to 40 percent of the patients with multiple myeloma - a type of leukaemia - have a defect in the ribosome, the protein factory of the cell.
12/09/16, News Medical Life Sciences

The defining DNA methylation signature of Floating-Harbor Syndrome

12/09/16, Nature

Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma

12/09/16, Nature

Role and mechanism of the AMPK pathway in waterborne Zn exposure influencing the hepatic energy metabolism of Synechogobius hasta

12/09/16, Nature

Genome maintenance and bioenergetics of the long-lived hypoxia-tolerant and cancer-resistant blind mole rat, Spalax: a cross-species analysis of brain transcriptome

12/09/16, Nature

Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm

12/09/16, Nature

Corrigendum: Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids

12/09/16, Nature

TRBP ensures efficient Dicer processing of precursor microRNA in RNA-crowded environments

12/09/16, Nature

K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression

12/09/16, Nature

Ketogenesis contributes to intestinal cell differentiation

12/09/16, Nature

Chromatin environment, transcriptional regulation, and splicing distinguish lincRNAs and mRNAs
While long intergenic noncoding RNAs (lincRNAs) and mRNAs share similar biogenesis pathways, these transcript classes differ in many regards. LincRNAs are less evolutionarily conserved, less abundant, and more tissue-specific, suggesting that their pre- and post-transcriptional regulation is different from that of mRNAs. Here, researchers from Harvard University performed an in-depth characterization of the features that ...
12/09/16, lncRNA Research and Industry News

AnnoLnc – a web server for systematically annotating novel human lncRNAs
Long noncoding RNAs (lncRNAs) have been shown to play essential roles in almost every important biological process through multiple mechanisms. Although the repertoire of human lncRNAs has rapidly expanded, their biological function and regulation remain largely elusive, calling for a systematic and integrative annotation tool. Here researchers from Peking University present AnnoLnc, a one-stop portal ...
12/09/16, lncRNA Research and Industry News

RNA Modification Helps Drosophila Straighten Up and Fly Right
Absent a certain RNA modification, the flies folded their wings askew, lost their sense of direction, and wafted about listlessly—more listlessly than is ordinary. The RNA modification that the flies lacked is called m 6 A, which refers to the methylation of the nitrogen at position 6 of the adenosine base within messenger RNA (mRNA). The wobbly flies? They were part of a molecularly impaired squadron of Drosophila that had been prepared by scientists at the Institute of Molecular Biology (IMB) and Johannes Gutenberg University Mainz (JGU). The scientists, led by IMB researcher Jean-Yves Roignant, Ph.D., suggest that the m 6 A RNA modification is important for brain function. They add that since m 6 A is found in vertebrates as well as in flies, it could also affect brain function in humans. The scientists presented their findings December 8 in the journal Nature, in an article ...
12/09/16, Genetic Engineering & Biotech News

Personality Traits Mapped to Specific Genomic Locations
Nature vs. nurture has been a long-standing argument between the fields of biology and psychology. However, new data from researchers at University of California San Diego (UCSD) School of Medicine scores some points for biologists, as investigators have identified six loci or regions of the human genome that are significantly linked to personality traits. Moreover, the new findings also show correlations with psychiatric disorders.    “Although personality traits are heritable, it has been difficult to characterize genetic variants associated with personality until recent, large-scale genome-wide association studies, or GWAS," explained senior study investigator Chi-Hua Chen, Ph.D., assistant professor in the department of radiology at UCSD School of Medicine. The findings from this study were published recently in Nature in an article entitled “Genome-Wide Analyses for Personality Traits Identify Six Genomic Loci and Show Correlations with Psychiatric Disorders.” Five psychological factors are commonly used to measure individual ...
12/09/16, Genetic Engineering & Biotech News

Lilly and AstraZeneca Expand AD Partnership as Lilly Details Failed Solanezumab Study
Eli Lilly is paying AstraZeneca $30 million up front as part of a co-development deal that adds the latter’s Phase I-stage Alzheimer’s disease (AD) candidate MEDI1814 to the firms’ existing AD collaboration. Announcement of the deal coincides with Lilly separately reporting detailed data from the previously disclosed failed Phase III EXPEDITION3 study with its own anti-amyloid-beta (Aβ) monoclonal antibody AD candidate solanezumab. AstraZeneca’s MEDI1814 is an antibody targeting Aβ42, which the firm claims exhibits a unique mechanism of action among clinical-stage antibodies and could offer a new approach to treating AD. “We are excited to build on an already productive collaboration with Lilly, which combines the expertise of our two companies with a new program focused on the Aβ pathway," commented Mene Pangalos, evp, IMED Biotech Unit and Business Development at AstraZeneca. In September 2014, Lilly and AstraZeneca signed a potentially $500 million agreement to develop AZD3293, ...
12/09/16, Genetic Engineering & Biotech News

Forge and Evotec Ally on Superbug Inhibitors
Forge Therapeutics is partnering with Evotec for lead optimization of its LpxC inhibitor candidate in development against Gram-negative bacterial infections, including drug-resistant superbugs. San Diego-based startup Forge is exploiting a drug discovery platform that combines molecular modeling and rational drug design with expertise in bioinorganic chemistry to develop small-molecule inhibitors of metalloproteins. The firm maintains that its LpxC inhibitor is the first nonhydroxamate candidate to demonstrate in vivo efficacy in preclinical models of Gram-negative superbug infections. Evotec will contribute expertise in areas that include microbiology, structural biology, medicinal and computational chemistry, ADME, and PK. “...they provide significant preclinical expertise and added horsepower to rapidly advance our novel antibiotic to address this growing unmet global issue,” stated Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics. “Our LpxC inhibitors have proven to be stable, potent in vitro , and have shown preliminary efficacy in vivo .” In July 2016 ...
12/09/16, Genetic Engineering & Biotech News

Ex-CEO among Six Former Insys Executives Arrested on Subsys Racketeering Charges
The former CEO and president of Insys Therapeutics was among six former company executives who were arrested yesterday on federal charges of leading a nationwide conspiracy to bribe doctors to unnecessarily prescribe a fentanyl-based pain medication and defraud insurers. Michael L. Babich, 40, of Scottsdale, AZ, and the other five ex-Insys executives were accused of conspiring to bribe practitioners—many of them operators of pain clinics—to coax them into prescribing Subsys (fentanyl sublingual spray), a pain medication designed to treat cancer patients. In exchange for bribes and kickbacks, the practitioners wrote large numbers of prescriptions for the patients, most of whom were not diagnosed with cancer, the U.S. Attorney’s Office alleges in its indictment. According to the indictment, Babich and the other former Insys executives conspired to mislead and defraud health insurance providers by setting up a “reimbursement unit” dedicated to obtaining prior authorization directly from insurers ...
12/09/16, Genetic Engineering & Biotech News

AstraZeneca to Eliminate 700 U.S. Jobs
AstraZeneca plans to eliminate approximately 700 U.S. jobs and cut spending in its commercial business operations, blaming the likelihood of lower revenues next year due to loss of exclusivity for some of its blockbuster drugs. The job cuts will occur across the U.S., and include the North America Commercial headquarters, as well as “some” field-based sales and field-based non-sales positions, AstraZeneca said yesterday in a statement. Approximately 80 of the cuts will come from existing positions. “We continue to face loss of exclusivity impacts from many of our legacy products and work to compete in an ever-changing external environment,” the company stated. That loss of exclusivity has resulted in generic competitors to two of its branded prescription drugs. Nexium® (esomeprazole), the proton-pump inhibitor that reduces stomach acid, lost its monopoly last year. The anti-cholesterol statin Crestor® (rosuvastatin calcium) has faced competition from an Allergan generic ...
12/09/16, Genetic Engineering & Biotech News

Anti-CRISPR Protein Is Gene Editing “Off-Switch”
Scientists at the UMass Medical School and the University of Toronto say they have discovered the first known "off-switches" for CRISPR/Cas9 activity, providing much greater control over the edits, according to a new study ("Naturally Occurring Off-Switches for CRISPR-Cas9") published in Cell.  Erik J. Sontheimer, Ph.D., professor in the RNA Therapeutics Institute at UMass Medical School, along with Alan Davidson, Ph.D., professor of molecular genetics, and Karen Maxwell, Ph.D., assistant professor of biochemistry, at the University of Toronto, identified three naturally occurring proteins that inhibit the Cas9 enzyme. These proteins, known as anti-CRISPRs, have the ability to block DNA cleavage by the Cas9 nuclease. "CRISPR/Cas9 is a good thing because it introduces specific chromosome breaks that can be exploited to create genome edits, but because chromosome breakage can be hazardous, it is possible to have too much of a good thing, or to have it go on for too ...
12/09/16, Genetic Engineering & Biotech News

Supreme Court urged to weigh in on six-month biosimilar delays
Supreme Court urged to weigh in on six-month biosimilar delays arlene.weintraub Fri, 12/09/2016 - 09:21
12/09/16, Fierce Pharma

Mylan scores review of Allergan's Restasis IP, but analysts aren't worried about the med's fate
Mylan scores review of Allergan's Restasis IP, but analysts aren't worried about the med's fate chelfand Fri, 12/09/2016 - 10:45
12/09/16, Fierce Pharma

FiercePharmaAsia: Takeda-Lightstone’s neuroscience JV, China’s accelerating cancer research, Sun’s Halol plant, and more
FiercePharmaAsia: Takeda-Lightstone’s neuroscience JV, China’s accelerating cancer research, Sun’s Halol plant, and more aliu Fri, 12/09/2016 - 09:43
12/09/16, Fierce Pharma

Perrigo offloads India plant to Strides Shasun
Perrigo offloads India plant to Strides Shasun epalmer Fri, 12/09/2016 - 10:47
12/09/16, Fierce Pharma

Three proteins may help control unwanted CRISPR-Cas9 gene edits
Three proteins may help control unwanted CRISPR-Cas9 gene edits arlene.weintraub Fri, 12/09/2016 - 10:34
12/09/16, Fierce Biotech

Study: IBM Watson agrees with cancer docs on treatment options 90% of the time
Study: IBM Watson agrees with cancer docs on treatment options 90% of the time aalidrus Thu, 12/08/2016 - 19:19
12/09/16, Fierce Biotech

Medtronic integrates CGM, Fitbit data into mobile app
Medtronic integrates CGM, Fitbit data into mobile app aalidrus Fri, 12/09/2016 - 10:17
12/09/16, Fierce Biotech

Leerink goes to bat for AstraZeneca, naming it top stock pick for 2017 on strength of ‘underappreciated’ pipeline
Leerink goes to bat for AstraZeneca, naming it top stock pick for 2017 on strength of ‘underappreciated’ pipeline nick.paul.taylor Fri, 12/09/2016 - 06:35
12/09/16, Fierce Biotech

Analysts on amyloid thesis: It's not dead yet
Analysts on amyloid thesis: It's not dead yet badams Fri, 12/09/2016 - 04:53
12/09/16, Fierce Biotech

After phase 3 failures, Lilly signs new Alzheimer’s drug pact with AstraZeneca
After phase 3 failures, Lilly signs new Alzheimer’s drug pact with AstraZeneca badams Fri, 12/09/2016 - 07:40
12/09/16, Fierce Biotech

Q&A: What are exosomes, exactly?
What is the current definition of an exosome? That is a very good question. Since the original description of exosomes over 30 years ago, the term has been loosely used for various forms of extracellular vesicle, muddying the field and contributing to the scepticism with which the research has sometimes been met. Exosomes are best ...
12/09/16, Exosome RNA Research & Industry News

Astrocytes and Exosomes Implicated in Protein Propagation
Alzfoum – Many researchers now believe that misfolded proteins spread from cell to cell across the brain, corrupting normal proteins as they go, yet exactly how this propagation would happen remains unclear. At the Society for Neuroscience annual meeting, held November 12-16 in San Diego, scientists identified specific mechanisms that may be involved in the ...
12/09/16, Exosome RNA Research & Industry News

An anti-CRISPR for gene editing
Researchers have discovered a way to program cells to inhibit CRISPR-Cas9 activity. 'Anti-CRISPR' proteins had previously been isolated from viruses that infect bacteria, but now scientists report three families of proteins that turn off CRISPR systems specifically used for gene editing. The work offers a new strategy to prevent CRISPR-Cas9 technology from making unwanted changes.
12/08/16, ScienceDaily

NIH competition seeks wearable device to detect alcohol levels in real-time
NIAAA seeks innovative designs that use alternatives to measuring BAC through sweat.
12/08/16, National Institutes of Health

Phages Carry Antibiotic Resistance Genes
Researchers find evidence of antibiotic resistance genes in the DNA of viruses that infect bacteria.
12/08/16, The Scientist

SeqPlots – Interactive software for exploratory data analyses, pattern discovery and visualization in genomics
Experiments involving high-throughput sequencing are widely used for analyses of chromatin function and gene expression. Common examples are the use of chromatin immunoprecipitation for the analysis of chromatin modifications or factor binding, enzymatic digestions for chromatin structure assays, and RNA sequencing to assess gene expression changes after biological perturbations. To investigate the pattern and abundance ...
12/08/16, Transcriptome Research & Industry News

How well do RNA-Seq differential gene expression tools perform in higher eukaryotes?
RNA-seq experiments are usually carried out in three or fewer replicates. In order to work well with so few samples, Differential Gene Expression (DGE) tools typically assume the form of the underlying distribution of gene expression. A recent highly replicated study revealed that RNA-seq gene expression measurements in yeast are best represented as being drawn ...
12/08/16, Transcriptome Research & Industry News

CountClust – Visualizing the Structure of RNA-seq Expression Data using Grade of Membership Models
Grade of membership models, also known as “admixture models”, “topic models” or “Latent Dirichlet Allocation”, are a generalization of cluster models that allow each sample to have membership in multiple clusters. These models are widely used in population genetics to model admixed individuals who have ancestry from multiple “populations”, and in natural language processing to ...
12/08/16, Transcriptome Research & Industry News

UK slaps Pfizer with record £84.2m fine for unfair drug pricing
Pfizer and Flynn Pharma have been fined nearly £90 million by the UK's Competition and Markets Authority (CMA) for deliberately unbranding an anti-epilepsy drug to enable excessive price hikes.
12/08/16, PharmaTimes

EU expands use of Novartis’ eye drug Lucentis
The treatment scope of Novartis' Lucentis has been expanded in Europe to include patients with visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD), or secondary to pathologic myopia (PM).
12/08/16, PharmaTimes

EMA to review Regeneron, Sanofi’s atopic dermatitis biologic
European regulators have accepted for review Regeneron and Sanofi's application to market Dupixent for the treatment of certain adults with atopic dermatitis.
12/08/16, PharmaTimes

AZ’ Lisa Anson elected as ABPI president
AstraZeneca UK's president Lisa Anson is to take over the reigns of President of the Association of the British Pharmaceutical Industry.
12/08/16, PharmaTimes

AbbVie’s Venclyxto OK’d in Europe for CLL
Patients with difficult to treat forms of chronic lymphocytic leukaemia (CLL) have gained a new treatment option after the European Commission issued a green light for AbbVie's Venclyxto.
12/08/16, PharmaTimes

Plant-based foods containing cell wall polysaccharides rich in specific active monosaccharides protect against myocardial injury in rat myocardial infarction models

12/08/16, Nature

Peptidylarginine deiminase 1-catalyzed histone citrullination is essential for early embryo development

12/08/16, Nature

Caveolin-1 is an aggresome-inducing protein

12/08/16, Nature

Single Molecular Demonstration of Modulating Charge Inversion of DNA

12/08/16, Nature

TGF-β regulates phosphorylation and stabilization of Sox9 protein in chondrocytes through p38 and Smad dependent mechanisms

12/08/16, Nature

GSK-3β controls NF-kappaB activity via IKKγ/NEMO

12/08/16, Nature

RNAi-mediated mortality of the whitefly through transgenic expression of double-stranded RNA homologous to acetylcholinesterase and ecdysone receptor in tobacco plants

12/08/16, Nature

Methionine sulfoxides in serum proteins as potential clinical biomarkers of oxidative stress

12/08/16, Nature

Corrigendum: Identification of a 5-Methylcytosine Site that may Regulate C/EBPβ Binding and Determine Tissue-Specific Expression of the BPI Gene in Piglets

12/08/16, Nature

Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies

12/08/16, Nature

CCT complex restricts neuropathogenic protein aggregation via autophagy

12/08/16, Nature

Chromatin-remodelling factor Brg1 regulates myocardial proliferation and regeneration in zebrafish

12/08/16, Nature

Export of piRNA precursors by EJC triggers assembly of cytoplasmic Yb-body in Drosophila

12/08/16, Nature

Multi-dimensional super-resolution imaging enables surface hydrophobicity mapping

12/08/16, Nature

Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus

12/08/16, Nature

Widening perspectives on regenerative processes through growth

12/08/16, Nature

Spaceflight modulates gene expression in the whole blood of astronauts

12/08/16, Nature

Potential of Long Non-coding RNAs in Cancer Patients: From Bio-markers to Therapeutic Targets
Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a bio-marker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer, and ...
12/08/16, lncRNA Research and Industry News

Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis
Each year, over 16,000 patients die from malignant brain cancer in the US. Long noncoding RNAs (lncRNAs) have recently been shown to play critical roles in regulating neurogenesis and brain tumor progression. To better understand the role of lncRNAs in brain cancer, we performed a global analysis to identify and characterize all annotated and novel ...
12/08/16, lncRNA Research and Industry News

Transcriptic Adds Agilent Products to Robotic Cloud Laboratory
Agilent and Transcriptic have agreed to a collaboration through which Transcriptic is adding a number of Agilent genomics products for mutagenesis and cloning to its robotic cloud laboratory. The first Agilent technology to be included in Transcriptic's protocol library and laboratory is Agilent QuikChange Lightning for site-directed mutagenesis.   Transcriptic’s cloud-based service allows users to design their molecular biology experiments through a web-based portal, have them run on Transcriptic’s fully automated cell and molecular biology laboratory, and then have the results available for viewing anywhere in the world. The companies claim that providing Agilent bioreagents in a robotic laboratory setting will offer optimized workflows for customers. “Agilent QuikChange site-directed mutagenesis kits have an unsurpassed reputation for being reliable and easy to use,” said Yvonne Linney, COO, Transcriptic. “By bringing these products to Transcriptic, we will make it extremely easy for customers to scale up their research, using ...
12/08/16, Genetic Engineering & Biotech News

TCR2 Therapeutics Squares Up with 44.5M in Series A Financing
TCR 2 Therapeutics, an immuno-oncology company located in the heart of Kendall Square in Cambridge, MA, launched after securing $44.5 million in financing, led by MPM Capital and F2 Ventures. The company’s lead product is TRuC™, a T-cell receptor (TCR) fusion construct platform that can reprogram the TCR complex to recognize tumor antigens. The company has demonstrated this activity against both hematological and solid tumor targets in preclinical models. TCR 2 plans to develop its platform for a variety of highly differentiated T-cell therapies and advance its lead programs toward the clinic. "We are thrilled to bring TCR 2 out of stealth mode as it typifies the innovative start-ups we like to build in-house," said Ansbert Gadicke, M.D., MPM Capital co-founder and chairman of TCR 2 ’s board of directors. TCR 2 Therapeutics was founded last year by Patrick Baeuerle, Ph.D., managing director of MPM Capital ...
12/08/16, Genetic Engineering & Biotech News

Provectus, POETIC to Study Immunotherapy Candidate for Pediatric Cancers
Provectus Biopharmaceuticals said today it will partner with The Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) to study the company’s Phase III ablative immunotherapy candidate PV-10 as a potential treatment for childhood cancers. Provectus and the consortium have signed a joint research agreement establishing a framework for collaborative preclinical research projects the company may conduct with members of POETIC, a group of 10 top-tier academic medical centers developing new pediatric cancer therapies. The value of the research agreement was not disclosed. Provectus and POETIC did say, however, that their research program will collaborate with “a number of” NCI Cancer Centers that are part of the consortium, citing by name Memorial Sloan Kettering Cancer Center (MSK) and Alberta Children’s Hospital. PV-10 is an injectable formulation of Rose Bengal that is being studied as an ablative immunotherapy for solid-tumor cancers. Provectus has received FDA orphan drug designations for ...
12/08/16, Genetic Engineering & Biotech News

Horizon Pharma Drops Development of Actimmune for FA after Phase III Failure
Horizon Pharma is axing further development of its interferon gamma-1b protein therapy Actimmume® for the Friedreich’s ataxia (FA) indication, after a Phase III study missed both its primary and secondary endpoints. The placebo-controlled trial, Steadfast (Safety, Tolerability, and Efficacy of Actimmune Dose Escalation in Friedreich's Ataxia study), failed to show that Actimmune therapy resulted in statistically significant changes from baseline in the modified Friedreich’s ataxia rating scale (FARS-mNeuro), at 26 weeks. “While the results were not what we hoped for, this is the very reason why research and development is important— to find answers that may help inform future research,” stated Timothy P. Walbert, the firm’s chairman, president, and CEO. In May 2016 Horizon had reported licensing to an undisclosed third party the U.S., European, and Canadian IP rights to interferon gamma-1b for the FA indication. Also in May 2016 Horizon and Boehringer Ingelheim ...
12/08/16, Genetic Engineering & Biotech News

Heart Disease Biomarker Is Brain Damage Indicator
A new study lead by Dutch researchers at the Erasmus MC University Medical Center in Rotterdam has just uncovered evidence that increased levels of a peptide in the blood associated with heart disease are also linked to early-stage brain damage. The findings from the new study, which was published recently in the journal Radiology in an article entitled "N-Terminal Pro-B-Type Natriuretic Peptide and Subclinical Brain Damage in the General Population," imply a close link between the heart and brain even in presumably healthy individuals. Heart and brain disease inflict a toll on the healthcare system, and incidence rates are expected to increase significantly due to the rapidly aging population. Damage to both organs often occurs at a subclinical stage or before signs and symptoms of disease are evident. Biomarkers in the blood indicative of subclinical heart disease and brain diseases, such as stroke and dementia, could speed the ...
12/08/16, Genetic Engineering & Biotech News

For Some Tumor Cells, Fat Greases the Skids for Metastasis
Tumor cells that promote metastasis can be distinguished from tumor cells that do not, report scientists at the Institute for Research in Biomedicine (IRB Barcelona). According to these scientists, metastasis-inducing tumor cells have a particular taste for fat—very particular, in that they express high levels of the fatty acid receptor CD36 and lipid metabolism genes. These distinguishing features could, the scientists suggest, help predict metastasis and guide the development of new antimetastatic cancer therapies. They also help substantiate the observed link between high-fat diets and the heightened risk of certain kinds of cancer. IRB Barcelona researchers led by Salvador Aznar Benitah, Ph.D., discovered the metastatic CD36 + cells in samples from patients with oral cancer with different degrees of aggressiveness. In the mouth tumors analyzed, very few cells were found to have metastasis-initiating capacity. The addition of CD36 expression to tumors that had been free of metastasis made ...
12/08/16, Genetic Engineering & Biotech News

3D Chemokine Receptor Study Opens Door to Finding New Anti-Inflammatory Drugs
Scientists at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego have determined the 3D structure of CC chemokine receptor 2 (CCR2), a protein that sits on the surface of immune cells sensing and transmitting inflammatory signals that spur cell movement toward sites of inflammation, simultaneously bound to two inhibitors. Understanding how these molecules fit together may better enable pharmaceutical companies to develop anti-inflammatory drugs that bind and inhibit CCR2 in a similar manner.  CCR2 and associated signaling molecules are known to play roles in a number of inflammatory and neurodegenerative diseases, including multiple sclerosis, asthma, diabetic nephropathy, and cancer. Many drug companies have attempted to develop drugs that target CCR2, but none have yet made it to market.  "So far drugs that target CCR2 have consistently failed in clinical trials," said Tracy Handel, Ph.D., professor in the Skaggs School of Pharmacy. "One ...
12/08/16, Genetic Engineering & Biotech News

21st Century Cures Act Heads for Obama Signature After Senate Approval
The 21 st Century Cures Act is heading for signature into law by President Barack Obama, following its passage yesterday by the U.S. Senate in another lopsided bipartisan vote. The 94 to 5 Senate vote came a week after 21 st Century Cures overwhelmingly passed the U.S. House of Representatives by 392 to 26. Senate passage was all but assured on Monday when the Senate, with Vice President Biden presiding, approved by 85 to 13 a procedural “cloture” vote ending debate on the measure. Senators voting against 21 st Century Cures yesterday were Mike Lee (R-UT), Jeff Merkley (D-OR), Bernie Sanders (D-VT), Elizabeth Warren (D-MA), and Ron Wyden (D-OR). Sanders and Warren had spoken out publicly against the bill, asserting that it overly favored the interests of biopharma giants over patients and should have included provisions to contain rising prescription drug prices. Echoing that view ...
12/08/16, Genetic Engineering & Biotech News

Up to 80 Perrigo staffers face the ax in Belgium as struggling Omega unit gets a revamp
Up to 80 Perrigo staffers face the ax in Belgium as struggling Omega unit gets a revamp chelfand Thu, 12/08/2016 - 10:33
12/08/16, Fierce Pharma

Short seller calls Trump out to fight drug pricing. How? By 'firing' Express Scripts
Short seller calls Trump out to fight drug pricing. How? By 'firing' Express Scripts tracy Thu, 12/08/2016 - 16:03
12/08/16, Fierce Pharma

Pharma’s bad jobs week gets worse: AstraZeneca to cut 700 U.S. positions
Pharma’s bad jobs week gets worse: AstraZeneca to cut 700 U.S. positions esagonowsky Thu, 12/08/2016 - 15:54
12/08/16, Fierce Pharma

'Bribes,' 'kickbacks,' and 'fantastic' nights get ex-Insys CEO, execs indicted for conspiracy
'Bribes,' 'kickbacks,' and 'fantastic' nights get ex-Insys CEO, execs indicted for conspiracy esagonowsky Thu, 12/08/2016 - 14:29
12/08/16, Fierce Pharma

Endo to cut loose 375 sales reps, staffers as it sidelines pain meds
Endo to cut loose 375 sales reps, staffers as it sidelines pain meds chelfand Thu, 12/08/2016 - 09:12
12/08/16, Fierce Pharma

Top of 2017's pharma heap? Pfizer, Novartis, Roche—and 7 drugs headed for biosim attack
Top of 2017's pharma heap? Pfizer, Novartis, Roche—and 7 drugs headed for biosim attack esagonowsky Thu, 12/08/2016 - 10:27
12/08/16, Fierce Pharma

Ex-VP sues Bayer, saying she defended a pregnant colleague and got whacked for it
Ex-VP sues Bayer, saying she defended a pregnant colleague and got whacked for it esagonowsky Thu, 12/08/2016 - 10:02
12/08/16, Fierce Pharma

Teva, already facing $500M-plus penalties for bribery, probes claims it paid off docs in Romania
Teva, already facing $500M-plus penalties for bribery, probes claims it paid off docs in Romania chelfand Thu, 12/08/2016 - 11:31
12/08/16, Fierce Pharma

CMO Fareva opens U.S. aerosol plant, adding more than 80 jobs
CMO Fareva opens U.S. aerosol plant, adding more than 80 jobs epalmer Thu, 12/08/2016 - 10:12
12/08/16, Fierce Pharma

Pitt team creates protein that reverses CO poisoning in mice
Pitt team creates protein that reverses CO poisoning in mice aalidrus Thu, 12/08/2016 - 10:49
12/08/16, Fierce Biotech

Senate passes Cures, setting stage for regulatory rethink on combination products, device premarket approval process
Senate passes Cures, setting stage for regulatory rethink on combination products, device premarket approval process nick.paul.taylor Thu, 12/08/2016 - 11:22
12/08/16, Fierce Biotech

Regeneron, Sanofi’s hotly tipped atopic dermatitis drug dupilumab accepted for review at EMA
Regeneron, Sanofi’s hotly tipped atopic dermatitis drug dupilumab accepted for review at EMA nick.paul.taylor Thu, 12/08/2016 - 05:56
12/08/16, Fierce Biotech

Parkinson’s gene therapy data sparks Voyager stock jump
Parkinson’s gene therapy data sparks Voyager stock jump nick.paul.taylor Thu, 12/08/2016 - 03:13
12/08/16, Fierce Biotech

Immuno-oncology startup TCR2 promises to improve on CAR-T
Immuno-oncology startup TCR2 promises to improve on CAR-T phil Thu, 12/08/2016 - 08:17
12/08/16, Fierce Biotech

Horizon slumps after phase 3 Friedreich's ataxia trial flops
Horizon slumps after phase 3 Friedreich's ataxia trial flops nick.paul.taylor Thu, 12/08/2016 - 09:44
12/08/16, Fierce Biotech

Eutilex gains $18.9M in Series A round, boosting I/O trial funds
Eutilex gains $18.9M in Series A round, boosting I/O trial funds badams Thu, 12/08/2016 - 03:35
12/08/16, Fierce Biotech

EuroBiotech Report: UniQure’s ASH fizzles, Sanofi filing, TiGenix IPO, $60M cancer financing and Amryt raises €20M
EuroBiotech Report: UniQure’s ASH fizzles, Sanofi filing, TiGenix IPO, $60M cancer financing and Amryt raises €20M nick.paul.taylor Thu, 12/08/2016 - 08:47
12/08/16, Fierce Biotech

EuroBiotech:​​ ​​More​​ ​​Articles​​ ​​of​​ ​​Note
EuroBiotech:​​ ​​More​​ ​​Articles​​ ​​of​​ ​​Note nick.paul.taylor Thu, 12/08/2016 - 08:38
12/08/16, Fierce Biotech

An easy pass for Cures; so too for new meds?
An easy pass for Cures; so too for new meds? badams Thu, 12/08/2016 - 03:00
12/08/16, Fierce Biotech

Chutes & Ladders: FDA’s new drugs director to retire after Sarepta’s Exondys 51 fallout
Chutes & Ladders: FDA’s new drugs director to retire after Sarepta’s Exondys 51 fallout aliu Thu, 12/08/2016 - 16:37
12/08/16, Fierce Biotech

Exosome-Based Gene Therapy for MicroRNA Delivery
Despite recent advances in scientific knowledge and clinical practice, cardiovascular disease management and treatment remain a major burden. While several treatment strategies using drugs and surgeries are being developed for cardiovascular manifestations, gene-based therapies hold significant promise. Recent findings by researchers at the Icahn School of Medicine unveiled a novel mechanism that exosomes, secreted nanovesicles from ...
12/08/16, Exosome RNA Research & Industry News

Biocartis Group NV: Biocartis launches second liquid biopsy assay
Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of its second liquid biopsy assay, the Idylla(TM) ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading ...
12/08/16, Exosome RNA Research & Industry News

Cellular immunotherapy targets a common human cancer mutation
Researchers identified a method for targeting the cancer-causing protein produced by a mutant form of the KRAS gene.
12/07/16, National Institutes of Health

Merck to Lead Anti-CD27 Antibody into Clinical Testing as Immunotherapy for Cancer

immunotherapyMerck has selected an anti-CD27 antibody, an immunotherapy developed by an Aduro Biotech subsidiary, to advance into clinical testing based on its potential to activate a strong anti-cancer immune response. “Pre-clinical studies have shown that an anti-CD27 agonist can induce a T cell-mediated anti-cancer immune response, and in combination with PD-1 immune checkpoint inhibitors complete tumor eradication can be achieved,” […]

The post Merck to Lead Anti-CD27 Antibody into Clinical Testing as Immunotherapy for Cancer appeared first on Immuno-Oncology News.


12/07/16, Immuno-Oncology News

PubPeer Wins Appeal on Anonymous Comments
The Michigan Court of Appeals rules that anonymous commenters on the post-publication peer review website are protected under the First Amendment.
12/07/16, The Scientist

Toward Treating Alzheimer?s Disease with Brain Waves
In a mouse model, researchers mitigated three Alzheimer’s disease–associated symptoms by stimulating gamma waves with light.
12/07/16, The Scientist

Controlled Splicing Extends Life Span in Roundworms
Increasing the expression of an RNA splicing factor mimics dietary restriction, prolonging life in nematodes. 
12/07/16, The Scientist

Arguments Heard in CRISPR Patent Battle
The highly publicized legal fight over the intellectual property rights for CRISPR gene-editing technology comes to a head, as both sides present oral arguments.
12/07/16, The Scientist

The Pitfalls of RNA-Seq Methodology
TP53 undergoes multiple RNA-splicing events, resulting in at least nine mRNA transcripts encoding at least 12 functionally different protein isoforms. Antibodies specific to p53 protein isoforms have proven difficult to develop, thus researchers must rely on the transcript information to infer isoform abundance. In this study, researchers from the University of Otago used deep RNA-seq, ...
12/07/16, Transcriptome Research & Industry News

A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor
Single-cell RNA sequencing (scRNA-seq) is widely used to profile the transcriptome of individual cells. This provides biological resolution that cannot be matched by bulk RNA sequencing, at the cost of increased technical noise and data complexity. The differences between scRNA-seq and bulk RNA-seq data mean that the analysis of the former cannot be performed by ...
12/07/16, Transcriptome Research & Industry News

A new University of Pennsylvania effort is bringing RNA sequencing into high school classrooms through a free online resource
The goal is to make it easier for science teachers to incorporate the latest advances in science into their curricula. The initiative, Discovering the Genome, was spearheaded by Kristin Field, director of programs at Penn’s Nano/Bio Interface Center, and Junhyong Kim, professor of biology in the School of Arts & Sciences. Working with researchers around ...
12/07/16, Transcriptome Research & Industry News

US expands scope of Avastin in ovarian cancer
The US Food and Drug Administration has approved Roche-group Genentech's application to market Avastin for patients with a specific type of ovarian cancer.
12/07/16, PharmaTimes

Lung cancer surgery survival rates on the rise
Survival rates following lung cancer surgery are continuing to rise as the number of operations to treat the disease increases, finds a new report published by the Royal College of Physicians (RCP) and the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS).
12/07/16, PharmaTimes

EU green light for BMS’ Opdivo in blood cancer
EU regulators have issued a green light for the use of Bristol-Myers Squibb's Opdivo to treat the rare and often aggressive blood cancer classical Hodgkin lymphoma (cHL).
12/07/16, PharmaTimes

AZ’ Tagrisso beats chemo in lung cancer trial
Late-stage data show that AstraZeneca's Tagrisso extended the time lung cancer patients carrying a particular mutation lived without their disease worsening, potentially signalling a new standard of care in the second-line setting.
12/07/16, PharmaTimes

Identification of protein structural elements responsible for the diversity of sequence preferences among Mini-III RNases

12/07/16, Nature

Replicatively senescent human fibroblasts reveal a distinct intracellular metabolic profile with alterations in NAD+ and nicotinamide metabolism

12/07/16, Nature

Stem cells: HSC function determined by epigenetic memory

12/07/16, Nature

Transcriptional bursting is intrinsically caused by interplay between RNA polymerases on DNA

12/07/16, Nature

MALAT1 and HOTAIR Long Non-Coding RNAs Play Opposite Role in Prostate Cancer Cells
In the complex network of nuclear hormone receptors, the long non-coding RNAs (lncRNAs) are emerging as critical determinants of hormone action. Here researchers from the Institute of Cell Biology and Neurobiology, Rome investigated the involvement of selected cancer-associated lncRNAs in Estrogen Receptor (ER) signaling. Prior studies by Chromatin Immunoprecipitation (ChIP) Sequencing showed that in prostate ...
12/07/16, lncRNA Research and Industry News

Long intergenic non-coding RNA expression signature in human breast cancer
Breast cancer is a complex disease, characterized by gene deregulation. There is less systematic investigation of the capacity of long intergenic non-coding RNAs (lincRNAs) as biomarkers associated with breast cancer pathogenesis or several clinicopathological variables including receptor status and patient survival. Researchers at the Vanderbilt University Medical Center designed a two-stage study, including 1,000 breast ...
12/07/16, lncRNA Research and Industry News

Panel Hears Oral Arguments in CRISPR Patent Battle Royal
The latest skirmish in the bitter legal battle royal over who invented CRISPR ( clustered regularly interspaced short palindromic repeats) gene-editing technology played out yesterday before a three-judge panel of the Patent Trial and Appeal Board (PTAB) in Alexandria, VA. In oral arguments to the judges, the University of California (UC) Berkeley and Emmanuelle Charpentier, Ph.D., of the Helmholtz Centre for Infection Research presented their case for challenging the awarding of 12 patents related to CRISPR technology that list as inventor Feng Zhang, Ph.D., of the Broad Institute of MIT and Harvard. Some of the 12 list additional colleagues as inventors. The judges heard oral arguments—limited to 20 minutes on each side—as they move to decide whether an “interference” proceeding aimed at resolving the impasse can proceed, as declared in January by Administrative Patent Judge Deborah Katz of the U.S. Patent and Trademark Office (USPTO). “What ...
12/07/16, Genetic Engineering & Biotech News

Molecular Switch Finding May Help Drive Stem Cells to Desired Cell Type
Scientists at the Babraham Institute have revealed a new understanding of the molecular switches that control gene activity in human embryonic stem cells. This insight provides new avenues for improving the efficiency of being able to drive stem cells to create a desired cell type, an essential requirement to fulfill their promise in regenerative medicine, according to the researchers. In the developing embryo and during the specialization of stem cells, the activity of genes must be tightly controlled by epigenetics so that the correct genes are switched on and off at the right time and in the right cells. One of the main ways that this process is regulated is by a protein complex called Polycomb Repressive Complex 2 (PRC2), which keeps genes switched off until they are needed. It is known from previous studies that PRC2 is necessary for controlling gene activity during the development of the fruit ...
12/07/16, Genetic Engineering & Biotech News

Lonza Sells Peptides Operations to PolyPeptide Group
Lonza has agreed to sell its peptides business and operations in Braine-l’Alleud, Belgium, to The PolyPeptide Group for an undisclosed price, the companies said today. “The peptides chemical business is a niche business for Lonza, with only limited synergies with other small-molecule technologies,” Marc Funk, COO of Lonza’s Pharma&Biotech segment, said in a statement. “This move will also allow us to fully focus on our many other technologies, which we will continue to develop further.” The sale includes Lonza’s Braine facility, until now the company’s center for peptide chemical development and manufacturing. Approximately 280 employees are based at the Braine site, which the companies said will provide for PolyPeptide immediate access to additional large-scale capacity in synthesis, purification, and isolation of peptides. Lonza acquired the Braine peptide business in 2006 from UCB. The companies said the acquisition will not affect ongoing operations at the Braine facility ...
12/07/16, Genetic Engineering & Biotech News

Live Brain Imaging Shows Cerebral Malaria’s Detrimental Effects
Using state-of-the-art brain imaging technology, scientists at the National Institutes of Health filmed what happens in the brains of mice that developed cerebral malaria (CM). The results reveal the processes that lead to fatal outcomes of the disease and suggest an antibody therapy that may treat it.  
12/07/16, Genetic Engineering & Biotech News

Leon-Nanodrugs and Instillo Partner on Nanoparticle Oncology Drug
Germany’s Instillo group and leon-nanodrugs are partnering to develop a generic oncology drug using the latter’s proprietary MicroJetReactor (MJR®) nanotechnology platform. leon’s MJR technology has been developed as what the firm claims is a one-step, easily scalable bottom-up continuous precipitation process that addresses issues of poor drug solubility and bioavailability by reformulating new and existing oral and parenteral drugs as nanoparticles. The technology can be applied to small molecule and peptide- or protein-based molecules to generate naked, polymer-coated, or functionalized nanoparticles. The generic oncology drug being developed as part of the Instillo partnership will be produced at Ursapharm, in Germany. leon-nanodrugs CEO, Theron E. Odlaug, said that a partner will be sought for commercialization of the product when bioequivalence has been established. “Through the unique attributes of our MicroJet Reactor Technology, our goal is to generate added value to both established molecules and novel NCEs,” he ...
12/07/16, Genetic Engineering & Biotech News

Humans Rely on RNAi to Fight the Flu
It is an antiviral mechanism had been found in plants, insects, and nematodes—and mice, too—but it had not been found in humans…until now. Alas, the protective countermeasure, which depends on the creation of small interfering (siRNAs) in infected cells, is sometimes frustrated by viral counter-countermeasures. Nonetheless, it is significant that we have learned that we, like other species, possess this kind of protective countermeasure, which is called RNA interference (RNAi). Now that we  have it, we might find ways to strengthen it. A more robust RNAi antiviral response would help us fight not only influenza, but other RNA viruses such as Ebola, West Nile, and Zika. The new discovery was made by researchers from Massachusetts General Hospital (MGH) and the University of California, Riverside. In their report receiving advance online publication in Nature Microbiology (“Induction and Suppression of Antiviral RNA Interference by Influenza A Virus in Mammalian Cells”), ...
12/07/16, Genetic Engineering & Biotech News

Gladstone’s BioFulcrum Produces Tenaya, Leveraging $50M to Cure Heart Disease
Building on research at the Gladstone Institutes, Tenaya Therapeutics, a new biopharmaceutical company, will concentrate on regenerative medicine and drug discovery for cardiovascular diseases. The new company is supported by $50 million in Series A financing from The Column Group. JJ Kang, Ph.D., an associate at The Column Group, is the president of the new company. Tenaya is the first company to be created from BioFulcrum, the entrepreneurial initiative within Gladstone, that started in January, 2015. The new company plans to leverage Gladstone’s work with cellular reprogramming in their research, including regenerating heart muscles and creating stem-cell derived heart models for pharmaceutical development.
12/07/16, Genetic Engineering & Biotech News

Genetically Engineered Mosquitoes Waved Through Here, Swatted Down There
After referenda in two Florida communities, one favoring and one rejecting the release of genetically engineered mosquitoes, the Board of the Florida Keys Mosquito Control District (FKMCD) has issued contrasting decisions—one supporting the release in Monroe County, where 57% of voters said “yea,” and the other rejecting the release in Key Haven, where 65% of voters said “nay.” The FKMCD decisions followed the voter totals even though the referenda, which took place November 8, were nonbinding. The Monroe County decision was highlighted in a press release issued by Oxitec, the company that produces the OX513A mosquito, a transgenic strain the company hopes to release once all commercial approvals have been secured. OX513A mosquitoes carry a gene that they pass to their offspring after mating with wild specimens of the Aedes aegypti mosquito, which is known to transmit the dengue, Zika, and chikungunya viruses. The gene causes ...
12/07/16, Genetic Engineering & Biotech News

EC Clears Sixth Lucentis Indication; Novartis/Ophthotech Continue Combination Therapy for wet AMD
The European Commission has approved Novartis’ Lucentis® (ranibizumab) as a treatment for patients with visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD), or secondary to pathologic myopia (PM). Novartis said the antibody fragment VEGF-A inhibitor is the first retinal therapy approved for these indications. Regulatory clearance for this sixth indication for Lucentis covers all 28 European member states, along with Iceland, Liechtenstein, and Norway. Regulatory submissions have been filed in an additional 11 countries. The latest European approval was based on data from the Minerva study, which showed that Lucentis therapy resulted in a significant gain of visual acuity by approximately 10 letters at two months. This improvement was maintained for up to the full 12 months of the one-year study. Novartis maintains that ranibizumab has proven to be effective for the treatment of CNV, regardless of ...
12/07/16, Genetic Engineering & Biotech News

Abbott Sues to End Planned Acquisition of Alere
Abbott said today it filed a lawsuit seeking to end its proposed acquisition of Alere, citing a “substantial” loss in Alere's value in the nearly one year since the two companies disclosed plans to merge. Over the past year, shares of Alere had fallen 42% from a high of $54.11 on February 1—the day the acquisition was announced—sliding to $31.47 on July 27 before climbing back slowly, to yesterday’s close of $39.86, still down 26% from the high. The decline follows several developments since the merger announcement of February 1, including multiple government subpoenas. The company said on July 27 that its Alere Toxicology Services unit received a U.S. Department of Justice subpoena on July 1, seeking records related to Medicare, Medicaid and Tricare billings dating back to 2010 for patient samples tested at the company’s Austin, TX, pain management lab. In March, the company disclosed ...
12/07/16, Genetic Engineering & Biotech News

U.K. watchdog smacks Pfizer with record fine, citing a 2,600% price hike
U.K. watchdog smacks Pfizer with record fine, citing a 2,600% price hike tracy Wed, 12/07/2016 - 08:08
12/07/16, Fierce Pharma

Trump takes aim at pharma, promising 'I'm going to bring down drug prices'
Trump takes aim at pharma, promising 'I'm going to bring down drug prices' chelfand Wed, 12/07/2016 - 13:23
12/07/16, Fierce Pharma

With $496M CNS sale, Novartis joins the herd of pharmas casting off tired meds
With $496M CNS sale, Novartis joins the herd of pharmas casting off tired meds arlene.weintraub Wed, 12/07/2016 - 09:14
12/07/16, Fierce Pharma

Mylan eyes up to 3,500 layoffs in post-M&A cost-cutting drive
Mylan eyes up to 3,500 layoffs in post-M&A cost-cutting drive esagonowsky Wed, 12/07/2016 - 08:25
12/07/16, Fierce Pharma

Here's an FDA overhaul: Trump considers Thiel VC partner as commissioner, Bloomberg reports
Here's an FDA overhaul: Trump considers Thiel VC partner as commissioner, Bloomberg reports esagonowsky Wed, 12/07/2016 - 13:48
12/07/16, Fierce Pharma

Eli Lilly targets sales force for job cuts in wake of Alzheimer's failure
Eli Lilly targets sales force for job cuts in wake of Alzheimer's failure tracy Wed, 12/07/2016 - 11:33
12/07/16, Fierce Pharma

Celgene cuts work on 'encouraging' Abraxane regimen, turns to IO combos instead
Celgene cuts work on 'encouraging' Abraxane regimen, turns to IO combos instead chelfand Wed, 12/07/2016 - 11:34
12/07/16, Fierce Pharma

China’s healthcare reforms will shake up the country’s pharmaceutical market
China’s healthcare reforms will shake up the country’s pharmaceutical market aliu Wed, 12/07/2016 - 15:42
12/07/16, Fierce Pharma

Amgen teams with NPR-famed StoryCorps to collect and share myeloma stories
Amgen teams with NPR-famed StoryCorps to collect and share myeloma stories chelfand Wed, 12/07/2016 - 09:09
12/07/16, Fierce Pharma

Sun's key plant in Halol again cited by FDA
Sun's key plant in Halol again cited by FDA epalmer Wed, 12/07/2016 - 08:03
12/07/16, Fierce Pharma

Spanish API maker Interquim hit with FDA warning letter
Spanish API maker Interquim hit with FDA warning letter epalmer Wed, 12/07/2016 - 13:50
12/07/16, Fierce Pharma

Lonza to sell EU peptide plant to PolyPeptide group
Lonza to sell EU peptide plant to PolyPeptide group epalmer Wed, 12/07/2016 - 09:43
12/07/16, Fierce Pharma

Stem cell biomarker predicts leukemia patients' response to chemo
Stem cell biomarker predicts leukemia patients' response to chemo aalidrus Wed, 12/07/2016 - 14:39
12/07/16, Fierce Biotech

China fines Medtronic $17M in price-fixing crackdown
China fines Medtronic $17M in price-fixing crackdown aalidrus Wed, 12/07/2016 - 10:26
12/07/16, Fierce Biotech

Abbott files complaint to escape Alere deal gone sour
Abbott files complaint to escape Alere deal gone sour aalidrus Wed, 12/07/2016 - 12:48
12/07/16, Fierce Biotech

Linking to health records will help drive CTMS market, says study
Linking to health records will help drive CTMS market, says study phil Wed, 12/07/2016 - 13:23
12/07/16, Fierce Biotech

Regulus adds two more projects to pipeline as it works to get lead hep C drug back on track
Regulus adds two more projects to pipeline as it works to get lead hep C drug back on track phil Wed, 12/07/2016 - 08:47
12/07/16, Fierce Biotech

Nordic Nanovector bags $60M for Rituxan combo phase 2
Nordic Nanovector bags $60M for Rituxan combo phase 2 nick.paul.taylor Wed, 12/07/2016 - 09:16
12/07/16, Fierce Biotech

Neurimmune, TVM set up ALS biotech, secure support of Eli Lilly unit for advance toward clinical proof of concept
Neurimmune, TVM set up ALS biotech, secure support of Eli Lilly unit for advance toward clinical proof of concept nick.paul.taylor Wed, 12/07/2016 - 07:27
12/07/16, Fierce Biotech

AbbVie’s phase 2 PARP study misses survival endpoints; hopes rest on bigger phase 3
AbbVie’s phase 2 PARP study misses survival endpoints; hopes rest on bigger phase 3 badams Wed, 12/07/2016 - 04:02
12/07/16, Fierce Biotech

Upcoming Event – Exosomes in the CNS
Tuesday, March 21, 2017 | 12:00 PM – 5:00 PM The New York Academy of Sciences Presented by the Biochemical Pharmacology Discussion Group Extracellular vesicles have experienced increasing attention in recent years, as our understanding of the diversity of their function has expanded from simple waste disposal units to critical players in cellular communication. In ...
12/07/16, Exosome RNA Research & Industry News

A miRNA panel in peripheral blood exosomes as novel biomarkers
Progression of asymptomatic carotid artery stenosis (ACAS) in patients with >50% luminal narrowing is considered a potential risk factor for ischemic stroke; however, subclinical molecular biomarkers of ACAS progression are lacking. Recent studies suggest a regulatory function for several microRNAs (miRNAs) on the evolution of carotid plaque, but its role in ACAS progression is mostly ...
12/07/16, Exosome RNA Research & Industry News

Raising the curtain on cerebral malaria’s deadly agents
NIH scientists film inside mouse brains to uncover biology behind the disease.
12/06/16, National Institutes of Health

Findings on ‘Solid Stress’ in Tumors Could Spark Development of New Therapies

Solid stress cancerA study published in the first issue of the scientific journal Nature Biomedical Engineering has described new tools that enables researchers to determine the force exerted by the different solid components of a tumor — solid stress — improving understanding of tumor cells and progression. “It has long been known that tissue stiffness is higher than normal […]

The post Findings on ‘Solid Stress’ in Tumors Could Spark Development of New Therapies appeared first on Immuno-Oncology News.


12/06/16, Immuno-Oncology News

Rascaf – Improving Genome Assembly with RNA Sequencing Data
Abundant but short second-generation sequencing reads make assembly difficult, leading to fragmented genomes and gene annotations. Gene structure information from RNA sequences can be used to improve the completeness and contiguity of an assembly, but bioinformatics methods have been lacking. Researchers at Johns Hopkins School of Medicine have developed Rascaf, a highly efficient tool leveraging ...
12/06/16, Transcriptome Research & Industry News

Pfizer, Avillion’s Bosulif comes out on top in first-line CML trial
Pfizer and partner Avillion have presented data from a late-stage study showing that Bosulif was better than Novartis' Gleevec as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.
12/06/16, PharmaTimes

Novo files once-weekly GLP-1 analogue semaglutide
Novo Nordisk has filed its once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide with regulators on both sides of the Atlantic, seeking permission to market the drug for the treatment of adults with type II diabetes.
12/06/16, PharmaTimes

NHS England announces cancer services boost
NHS England's chief executive Simon Stevens has unveiled the first tranche of hospitals that will benefit from a major national investment in NHS radiotherapy machines, as well as a £200m fund to improve cancer services.
12/06/16, PharmaTimes

Kymab’s antibody shows early promise in GvHD prophylaxis
UK group Kymab has unveiled what it says are "remarkable" early stage results for its new antibody therapy KY1005 in animal models of acute graft-versus-host-disease (GvHD).
12/06/16, PharmaTimes

Global prescription meds spend to hit $1.5 trillion by 2021
Global spend on prescription drugs is forecast to hit nearly $1.5 trillion by 2021, rising 33 percent from 2016 levels even as annual growth slows from record levels seen in 2014 and 2015, according to a new report from the QuintilesIMS Institute for Healthcare Informatics.
12/06/16, PharmaTimes

AZ sells Rhinocoart Aqua rights to Cilag
AstraZeneca has completed the sale of rights to nasal spray Rhinocort Aqua to Johnson & Johnson group Cilag GmbH.
12/06/16, PharmaTimes

Long Noncoding RNAs in Metabolic Syndrome Related Disorders
Ribonucleic acids (RNAs) are very complex and their all functions have yet to be fully clarified. Noncoding genes (noncoding RNA, sequences, and pseudogenes) comprise 67% of all genes and they are represented by housekeeping noncoding RNAs (transfer RNA (tRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), and small nucleolar RNA (snoRNA)) that are engaged in ...
12/06/16, lncRNA Research and Industry News

Featured lncRNA Job – Research Associate – Center for Molecular Medicine and Genetics
Posting Number – 042369 Position Title – Research Associate Number of Vacancies – 1 School/College/Division/Institutes/Centers – 06 – School of Medicine Primary Department – H0656-Center Molecular Medicine/Genetics Essential Functions – A Research Associate position is available in the Center for Molecular Medicine and Genetics. The qualified individual is expected to work on a funded NIH ...
12/06/16, lncRNA Research and Industry News

TiGenix Hopes to Net $43M in IPO, Round Two
Today, TiGenix filed for an initial public offering with the U.S. SEC. TiGenix tried to propose this IPO last October, only to have the plan fall apart. The Belgian company hopes to net $42.9 million from this offering of $52.8 million worth of American Depositary Shares (ADS). It plans to offload 2.75 million ADS at $19.20 per ADS (one ADS equals 20 ordinary shares). The stock was last traded at 0.90€ ($0.96) per share on the Euronext Brussels market. With this IPO, TiGenix plans to further develop products from its adipose-derived stem cell technology platform. Nearly half of the estimated net from this offering will go to developing Cx601 to treat complex perianal fistulas in Crohn’s disease. The company plans to complete the process of technology transfer to Lonza for Cx601, file an IND to conduct a Phase III trial of Cx601, and recruit patients ...
12/06/16, Genetic Engineering & Biotech News

Specific HIV Curative Approach May Pose Danger to Patients' Brains
Experience has demonstrated that combination drug treatments have become successful at long-term control of human immunodeficiency virus (HIV) infection. However, the goal of totally wiping out the virus and curing patients has so far been stymied by HIV’s ability to hide out in cells and become dormant for long periods of time. Now a new study on simian immunodeficiency virus (SIV) in macaques finds that a proposed curative strategy could backfire and make things worse if the virus is lurking in the brain. One of the proposed curative strategies for HIV, known as “shock and kill,” first uses latency-reversing agents to wake up dormant viruses in the body, making them vulnerable to the patient’s immune system. The idea is that this, in combination with antiretroviral medicines, would wipe out the majority of infected cells. But based on a study of macaques with SIV, a group of researchers warns ...
12/06/16, Genetic Engineering & Biotech News

Sienna Snaps Up Creabilis for Topical Dermatology Portfolio and Platform Tech
Sienna Biopharmaceuticals has acquired U.K.-based speciality pharmaceuticals company, Creabilis, which is developing a portfolio of clinical and preclinical topical candidates for the treatment of inflammatory skin conditions. Under the terms of the deal, Sienna will make a undisclosed, upfront cash and stock-based payment to Creabilis, and potentially in excess of $150 million in future regulatory and commercial-dependent milestones. Creabilis has applied its low systemic exposure (LSE) Topical by Design technology platform to develop a Phase IIb-stage topical tropomyosin receptor kinase A (TrkA) inhibitor, SNA-120 (formerly CT327), for the treatment of pruritus and psoriasis. In addition, a topical TrkA/janus kinase 3 (JAK3) inhibitor, SNA-125 (previously CT340), is in late-stage preclinical development for the treatment of inflammatory skin conditions, including atopic dermatitis, psoriasis, and pruritus. Other Creabilis preclinical candidates have been developed with support from a European Union Seventh Framework for Research (FP7) grant. Sienna is ...
12/06/16, Genetic Engineering & Biotech News

Novartis and Ariad Separately Report Positive ALK Inhibitor Results
Data from a Phase III study evaluating Novartis’ selective anaplastic lymphoma kinase (ALK) gene inhibitor, Zykadia® (ceritinib), showed that first-line treatment with the drug resulted in a 45% reduction in the risk of disease progression in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC). The firm said in a statement that it is now in discussions with regulatory authorities with respect to the potential use of the drug to improve outcomes for patients with ALK+ advanced NSCLC. Results from the open-label, active-controlled Ascend-4 study found that patients treated using first-line Zykadia had a median progression-free survival (PFS) of 16.6 months, compared with 8.1 months for patients treated using chemotherapy with maintenance.  Additional data from Ascend-4 showed that patients taking Zykadia had an overall response rate (ORR) of 72.5%, compared with 26.7% for patients treated using standard chemotherapy. For patients with ...
12/06/16, Genetic Engineering & Biotech News

Genetic Housekeeping Nowhere without NoBody Microprotein
When it comes to used messenger RNA (mRNA), we know NoBody knows where it comes and where it goes. This NoBody, unlike the nobody of Aerosmith fame, may not inspire song, but it helps fulfill a vital function: mRNA recycling. NoBody, named for nonannotated P-body dissociating polypeptide, is a 7-kDa human microprotein. It is, like other microproteins, so small that it remains unseen unless special techniques are used. Yet it did not escape the notice of Salk Institute and Yale University researchers. They identified NoBody by using a technique that has revealed more than 400 new proteins. Details of the researchers’ work appeared December 5 in the journal Nature Chemical Biology, in an article entitled, “A Human Microprotein That Interacts with the mRNA Decapping Complex.” The article emphasizes that NoBody is notable not only because it enables a form of genetic housekeeping duties, but also because it ...
12/06/16, Genetic Engineering & Biotech News

FDA OND Director Jenkins to Retire
John K. Jenkins, M.D., director of the FDA’s Office of New Drugs (OND), will retire from the federal government on January 6, 2017, the agency has confirmed. Dr. Jenkins played a “pivotal role” in overseeing the FDA’s current managed new drug review process, or “21 st Century Review,” Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research (CDER), said yesterday in a memo to Center staffers. Dr. Woodcock will serve as acting OND director pending a successor to Dr. Jenkins, which she said will emerge following a national search. In his position, she said, Dr. Jenkins led OND in setting U.S. standards for new drugs’ safety and efficacy, overseeing clinical testing of investigational drugs and reviewing marketing applications under Prescription Drug User Fee Act (PDUFA) timelines. “He and his staff, which has grown to more than 1000, have successfully navigated many high-profile ...
12/06/16, Genetic Engineering & Biotech News

CRISPR Brings an Early Harvest
 
12/06/16, Genetic Engineering & Biotech News

Post-doc Positions Available – Epithelial Biology Center
Postdoctoral Fellowship Positions are immediately available within the Vanderbilt University Epithelial Biology Center. The Center is dedicated to the multi-disciplinary study of intra- and extra-cellular trafficking and signaling, establishment and maintenance of epithelial polarity, and role of intestinal stem cells in health and disease. Positions are immediately available in NIH-funded research programs to: characterize gastrointestinal ...
12/06/16, Exosome RNA Research & Industry News

Exosomes play an important role in the process of psoralen reverse multidrug resistance of breast cancer
Release of exosomes have been shown to play critical roles in drug resistance by delivering cargo. Targeting the transfer of exosomes from resistant cells to sensitive cells may be an approach to overcome some cases of drug resistance. In this study, researchers from Binzhou Medical University investigated the potential role of exosomes in the process ...
12/06/16, Exosome RNA Research & Industry News

Highly efficient genome engineering in flowering plants
Plant biologists have developed a genome editing method to knockout target genes in a model plant with high efficiency. The team reports a new CRISPR/Cas9 vector for the model plant that can strongly induce inheritable mutations. This method is expected to become a powerful molecular tool for genome engineering in various plant species.
12/05/16, ScienceDaily

No safe level of smoking: Even low-intensity smokers are at increased risk of earlier death
Less than one cigarette per day over a lifetime caused 64 percent higher risk of earlier death.
12/05/16, National Institutes of Health

Topical Psoriasis Medication May Help Fight Premalignant Skin Lesions, Study Suggests

topical psoriasis medicinePatients with actinic keratosis, a precursor of a type of skin cancer called squamous cell carcinoma, may markedly benefit from the combination of two topical drugs that have been used in the clinic for several years, according to a new study published in the Journal of Clinical Investigation. The study, “Randomized trial of calcipotriol combined with 5-fluorouracil […]

The post Topical Psoriasis Medication May Help Fight Premalignant Skin Lesions, Study Suggests appeared first on Immuno-Oncology News.


12/05/16, Immuno-Oncology News

Tissue-specific Co-expression of Long Non-coding and Coding RNAs Associated with Breast Cancer
Inference of the biological roles of lncRNAs in breast cancer development remains a challenge. Here, Indiana University researchers analyzed RNA-seq data in tumor and normal breast tissue samples from 18 breast cancer patients and 18 healthy controls and constructed a functional lncRNA-mRNA co-expression network. They revealed two distinctive co-expression patterns associated with breast cancer, reflecting ...
12/05/16, lncRNA Research and Industry News

Biogenesis and Transcriptional Regulation of Long Noncoding RNAs in the Human Immune System
The central dogma of molecular biology states that DNA makes RNA makes protein. Discoveries over the last quarter of a century found that the process of DNA transcription into RNA gives rise to a diverse array of functional RNA species, including genes that code for protein and noncoding RNAs. For decades, the focus has been ...
12/05/16, lncRNA Research and Industry News

Spark Therapeutics Licenses Selecta's SVP Platform, Options to Four Genetic Targets
Spark Therapeutics has gained exclusive worldwide rights to Selecta Biosciences’ Synthetic Vaccine Particles (SVP™) platform and exclusive options for up to four additional undisclosed genetic targets, through a deal that could generate up to $460 million-plus for Selecta, the companies said today. Selecta’s immune tolerance SVP is intended to suppress the formation of neutralizing antibodies to an adeno-associated virus (AAV) capsid when used in combination with gene therapies, without altering the therapeutic profile of the gene therapy. SVP will be co-administered with gene therapy targets that include Factor VIII for hemophilia A, Selecta and Spark said. “Selecta’s nanoparticle technology, which is undergoing preclinical testing in gene therapy, may prevent formation of neutralizing antibodies, and thus potentially enable redosing up to an optimal therapeutic profile by extending the reach of gene therapy to diseases that require higher doses or more extensive transduction of target cells than may be ...
12/05/16, Genetic Engineering & Biotech News

Sanofi Partners with JHL to Develop Biosimilars for Chinese Market
Sanofi is investing $80 million in biopharma JHL Biotech as part of a strategic collaboration to develop biologics for the Chinese and potentially other international markets. Under terms of the agreement Sanofi will also pay the Taiwan-based startup $21 million up front for exclusive rights to a proposed Rituximab biosimilar, along with options to other specified JHL pipeline products. JHL will take the lead in product development, registration, and manufacturing, while Sanofi will shoulder commercialization efforts in the Chinese market. JHL could receive milestones of up to $236 million, plus royalties. Sanofi said the partnership is in line with its commitment to invest in the development of high-quality biologic therapeutics for the Chinese market. “JHL has quickly developed leading capabilities in the development of biologics and I am confident that our alliance will positively impact lives of patients in areas of high unmet medical ...
12/05/16, Genetic Engineering & Biotech News

Restricting Interferon Signaling Can Reinforce Checkpoint Blockade
Checkpoint inhibitor drugs can take the brakes off the immune system’s response to cancer, but they often encounter resistance. It turns out that releasing one set of brakes often isn’t enough. Ways must be found to release multiple brakes, despite the growing risk of adverse side effects. An alternative approach, one recently explored by scientists based at the University of Pennsylvania School of Medicine, amounts to adjusting the master cylinder, which controls the pressure in an auto’s brake system. The Penn Medicine researchers assert that shutting down the interferon pathway may improve the response to checkpoint inhibitor drugs. The researchers point to the results of their preclinical study, which appeared December 1 in the journal Cell, in an article entitled “Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.” According to this article, the interferon pathway is critical to a tumor's resistance to immunotherapy. ...
12/05/16, Genetic Engineering & Biotech News

Novartis Confirms Plans to File BLA for CAR T-Cell Therapy During Early 2017
Novartis said it is on track to file a biologics licence application (BLA) with FDA during early 2017 for use of its investigational chimeric antigen receptor T-cell (CAR T) therapy, CTL019, in relapsed/refractory (r/r) pediatric patients and young adults with B-cell acute lymphoblastic leukemia. Submission to the European Medicines Agency (EMA) for approval of the drug in Europe is expected later in 2017.  Confirmation of the proposed CTL019 filing timelines follows the release of positive interim data from the global, registrational Phase II ELIANA study, which showed that 41 out of 50 (82%) patients achieved complete remission, or complete remission with incomplete blood count recovery, at three months post infusion with CTL019. No residual disease was observed in any patient with complete remission. Estimated relapse-free rate among responders was 60%, six months after infusion. Forty eight percent of enrolled patients experienced grade 3 or 4 cytokine release syndrome ...
12/05/16, Genetic Engineering & Biotech News

Life Sciences Researchers Win $15M in Breakthrough Prizes
Five life sciences researchers were honored last night as winners of the 2017 Breakthrough Prize in Life Sciences. The Breakthrough Prize in Life Sciences honors “transformative” advances toward understanding living systems and extending human life. One prize is dedicated to work that contributes to the understanding of neurological diseases. Prizes of $3 million each were presented to: Stephen J. Elledge of Harvard Medical School, the Brigham and Women’s Hospital, and Howard Hughes Medical Institute, for elucidating how eukaryotic cells sense and respond to damage in their DNA and providing insights into the development and treatment of cancer. Harry F. Noller of the University of California, Santa Cruz, for discovering the centrality of RNA in forming the active centers of the ribosome, the fundamental machinery of protein synthesis in all cells, thereby connecting modern biology to the origin of life and also explaining ...
12/05/16, Genetic Engineering & Biotech News

CAR T-Cell Immunotherapy Proves a Plus in Treatment-Resistant Chronic Lymphocytic Leukemia
In a small, early-phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, experimental CD19-targeting chimeric antigen receptor (CAR) T-cell immunotherapy developed at Seattle's Fred Hutchinson Cancer Research Center. The Fred Hutch scientists presented their findings at the American Society of Hematology Annual Meeting and Exposition in San Diego. Almost all of the 24 patients in the study had cancer that had advanced despite treatment with a newly approved drug, ibrutinib. Most patients also had chromosomal markers in their leukemia cells that put them at high risk, "predictors of a bad response to most standard therapies," said Cameron Turtle, M.D., a hematologist/oncologist in the Clinical Research Division at Fred Hutch. Dr. Turtle's presentation focused on the results in a subgroup of patients ...
12/05/16, Genetic Engineering & Biotech News

Biomarker Predicts Fatal Leukemia Development in Previously Treated Cancer Patients
Secondary malignancies are an unfortunate and often fatal reality of therapies for a variety of cancers. Even patients who have seemingly been successfully treated can develop a fatal form of leukemia, sometimes years later—a clinical scenario known as therapy-related myeloid neoplasms (t-MNs). While risk factors for the development of t-MNs are currently not well understood, a new study conducted by researchers at The University of Texas MD Anderson Cancer Center has revealed that preleukemic mutations, called clonal hematopoiesis, may predict whether patients develop the aggressive condition. The researchers found that clonal hematopoiesis appears to function as a biomarker for patients who develop t-MNs, which is recognized for its extremely poor prognosis. The findings from this study were published recently in The Lancet Oncology in an article entitled “Preleukaemic Clonal Haemopoiesis and Risk of Therapy-Related Myeloid Neoplasms: A Case-Control Study.” "Therapy-related myeloid neoplasms occur in about 5% of ...
12/05/16, Genetic Engineering & Biotech News

AbbVie Launches Cancer Collaborations with Johns Hopkins, Northwestern
AbbVie is launching collaborations with two research institutions aimed at advancing cancer-focused research and discovery, the biopharma and its partners said today, continuing a series of efforts by the company to boost its oncology R&D. The value was not disclosed for the 5-year collaborations, through which AbbVie will partner separately with The Johns Hopkins University School of Medicine and with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Both institutions and AbbVie said they will work in several areas of oncology research, which could include, lung, colorectal, breast, prostate, and hematological cancers in addition to other areas. Researchers from Johns Hopkins Medicine and the Lurie Cancer Center will be allowed to access new therapies developed by AbbVie for preclinical research funded under the agreement. The researchers will work with AbbVie research teams under the agreements, which give AbbVie the option to obtain exclusive licenses ...
12/05/16, Genetic Engineering & Biotech News

Kimera Labs Announces Stem Cell Exosome Production Facility in South Florida
Focus on cell-free approaches offers expanded therapeutic potential for regenerative medicine applications. Kimera Labs Inc, a specialty contract research organization, today announced the creation of a 6,000 sq ft, ISO:9001 certified exosome production facility in Miramar, Florida. As an FDA registered tissue facility, Kimera Labs Miramar will produce tissue specific mesenchymal stem cell derived exosomes ...
12/05/16, Exosome RNA Research & Industry News

DNA sequences within glioma-derived exosomes can cross the intact blood-brain barrier
Tumor-cell-secreted extracellular vesicles (EVs) can cross the disrupted blood-brain barrier (BBB) into the bloodstream. However, in certain gliomas, the BBB remains intact, which might limit EVs release. To evaluate the ability of tumor-derived EVs to cross the BBB, researchers at the HM Hospitals Research Foundation, Spain used an orthotopic xenotransplant mouse model of human glioma-cancer ...
12/05/16, Exosome RNA Research & Industry News

Sun Sentinel: Ocean Ridge Biosciences expands to 5,400-square foot facility
Read More...
12/05/16, ORB Company News

Revolutionary DNA-Editing Technique Tested in Patient for First Time

DNA editing techniqueA research team at the West China Hospital has become the first to inject a person with cells that have been genetically modified with the revolutionary CRISPR-Cas9 technique. The modified cells were injected into a patient with aggressive lung cancer as part of a Phase 1 clinical trial and researchers report the patient is doing well. […]

The post Revolutionary DNA-Editing Technique Tested in Patient for First Time appeared first on Immuno-Oncology News.


12/02/16, Immuno-Oncology News

PubPeer Loses Battle, Hopes to Win War on Anonymous Comments
Lawyers involved discuss the latest twist in the ongoing litigation that pits pathologist Fazlul Sarkar against anonymous commenters on the post-publication peer review site.
12/02/16, The Scientist

Naive T Cells Find Homes in Lymphoid Tissue
The human lymph nodes and spleen maintain unique, compartmentalized sets of naive T cells well into old age.
12/02/16, The Scientist

Opinion: An Ethical Code for Conferences
This fundamental form of scientific communication is threatened by modern recording technology and researchers who refuse to adhere to an age-old ethical code. 
12/02/16, The Scientist

Takeda Spins Out Research Team into Neuroscience Startup
Takeda Pharmaceutical has spun out its 25-person neuroscience research team in Cambridge, U.K., joining with Lightstone Ventures to help launch Cerevance, a new company focused on developing new treatments for neurological and psychiatric disorders. Cerevance will be led by Mark Carlton, Ph.D., who until now has been president and CSO of Takeda Cambridge. The company’s resources include a portfolio of preclinical and clinical-stage drug programs, lab space, and access to a new technology created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D., at The Rockefeller University. Cerevance has been funded with $36 million—including $21.5 million in Series A financing from Takeda and Lightstone. Representatives from each will join Cerevance’s board. “With a well-capitalized, proven team and promising drug programs already underway, we hope to rapidly advance a pipeline of therapeutics into the clinic in parallel with scaling up a truly novel approach to ...
12/02/16, Genetic Engineering & Biotech News

Survey of Approved Drugs Intended to Shed Light on Potential New Therapies
Researchers have created a map of all 1578 licensed drugs and their mechanisms of action as a means of identifying "uncharted waters" in the search for future treatments. Their analysis of drugs licensed through the U.S. FDA reveals that 667 separate proteins in the human body have had drugs developed against them—just an estimated 3.5% of the 20,000 human proteins. And as many as 70% of all targeted drugs created so far work by acting on just four families of proteins, thus leaving vast swathes of human biology untouched by drug-discovery programs. The study is the most comprehensive analysis of existing drug treatments across all diseases ever conducted. It was jointly led by scientists at The Institute of Cancer Research, London, which also funded the research. The new map reveals areas where human genes and the proteins they encode could be promising targets for new treatments and ...
12/02/16, Genetic Engineering & Biotech News

Parkinson’s Disease and Gut Microbiome Linked
Only a few decades ago, it would have been largely inconceivable that resident microbes of our digestive tract would play a significant role in neurological diseases. Though roughly 75% of patients with Parkinson’s disease (PD) have gastrointestinal (GI) abnormalities, primarily constipation, it had been assumed for many years that this was a side effect of neurodegeneration. However, in recent years, researchers have begun to uncover important links between microbial communities of the gut and neurological health. Now, a team of investigators led by scientists at the California Institute of Technology (Caltech) have discovered for the first time a functional link between bacteria in the intestines and PD. The researchers were able to show that changes in the composition of gut bacterial populations—or possibly gut bacteria themselves—are actively contributing to and may even cause the deterioration of motor skills that is the hallmark of this disease.   "We ...
12/02/16, Genetic Engineering & Biotech News

Engineered Flu Virus a Replicative Dud, but Stays Live
Developing a live vaccine is a tricky balancing act. But it can become more of a sure thing if the vaccine developer puts a thumb on the scales. That’s one way to describe the approach taken by Peking University researchers. They decided to tweak the influenza A virus genetically so that it would not only remain fully capable of activating the immune system, but would also be incapable of replicating in healthy cells. The secret? Well, that’s the proverbial thumb, which in this case is a cell line that makes use of an expanded genetic code. In cells of this line, viruses could replicate, but only in the presence of an unnatural amino acid. Details appeared December 2 in the journal Science, in an article entitled, “Generation of Influenza A Viruses as Live but Replication-Incompetent Virus Vaccines.” It described how the Peking University researchers, led by Demin ...
12/02/16, Genetic Engineering & Biotech News

Boehringer Ingelheim Axes 244 More U.S. Jobs
Boehringer Ingelheim has confirmed that it has eliminated 244 additional positions in the U.S. since July, three-quarters of them based at its U.S. headquarters in Ridgefield, CT. The pharma said the job cuts consisted of 64 sales positions nationwide and 180 headquarters positions—of which 120 were in small-molecule Discovery Research and the other 60 in administrative functions. In a statement, Boehringer Ingelheim said the layoff of the Ridgefield-based small-molecule researchers followed a company decision to consolidate small-molecule discovery activity in Biberach, Germany, and Vienna, Austria, and shut down operations in Ridgefield and Milan, Italy. “The actions we are taking now will help us reinvent the way we serve the needs of our patients and enable us to continue to identify new medical breakthroughs,” Boehringer Ingelheim said in a statement. Boehringer Ingelheim added that a leaner global Discovery Research organization will allow the company to step ...
12/02/16, Genetic Engineering & Biotech News

Modifying a live virus in a vaccine to be just strong enough
By genetically tweaking the constituent live virus, scientists have created a vaccine against influenza in which the virus is capable of activating the immune system but cannot replicate in healthy cells -- an approach that may become more widely used for generating live virus vaccines adapted to other viruses.
12/01/16, ScienceDaily

NIH Statement on World AIDS Day 2016
Annual awareness day focuses on development of effective treatments and prolonging the lives of those living with HIV.
12/01/16, National Institutes of Health

FDA Grants Priority Review to Avelumab for Metastatic Merkel Cell Carcinoma Treatment

FDA Granted Priority Review to AvelumabThe U.S. Food and Drug Administration (FDA) has accepted for Priority Review the investigational anti-PD-L1 avelumab for the treatment of metastatic Merkel cell carcinoma (MCC). The Priority Review status, which is granted to drugs that may provide significant improvements in  treatment, or may offer treatment where no adequate treatment exists, will decrease the FDA’s review […]

The post FDA Grants Priority Review to Avelumab for Metastatic Merkel Cell Carcinoma Treatment appeared first on Immuno-Oncology News.


12/01/16, Immuno-Oncology News

Retrieving Short-Term Memories
Neurons can continue to capture a short-term memory without continuous firing, researchers show.  
12/01/16, The Scientist

Gut Microbes Linked to Neurodegenerative Disease
Bacteria in the intestine influence motor dysfunction and neuroinflammation in a mouse model of Parkinson’s disease.
12/01/16, The Scientist

Collaborative Agreement Struck to Assess Combo Therapy in 8 Tumor Types

collaborative agreementHalozyme Therapeutics and Genentech have entered a collaborative agreement to assess the combination of their drug candidates PEGPH20 and Tecentriq (atezolizumab) in two clinical trials that will evaluate up to eight tumor types and begin in 2017. Genentech will lead an open-label, multi-arm, randomized, global Phase 1b/2 clinical trial, designed to evaluate the PD-L1 blocking […]

The post Collaborative Agreement Struck to Assess Combo Therapy in 8 Tumor Types appeared first on Immuno-Oncology News.


11/30/16, Immuno-Oncology News

Next Generation: Observing Cancer-Associated Mitochondrial Changes
A noninvasive microscopy technique that exploits NADH fluorescence enables researchers to observe how mitochondria alter their shape and arrangement in human tissue.
11/30/16, The Scientist

Q&A: Inside r/Science, the Internet?s Liveliest Scientific Forum
Four years ago, chemist Nate Allen helped turn an unruly message board into an open platform for in-depth conversations about science. 
11/30/16, The Scientist

Three-Parent IVF Advances
Differences in the replicative advantages conferred by some mitochondrial DNA haplotypes have implications for mitochondrial replacement therapy, researchers report. 
11/30/16, The Scientist

Juno Halts Clinical Trial of Leukemia Therapy for Second Time This Year

Juno clinical holdJuno Therapeutics has voluntarily halted its Phase 2 clinical trial evaluating the investigative therapy JCAR015 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The clinical hold, announced in a recent press release, was initiated after two more patients died with cerebral edema. Seattle-based Juno notified the U.S. Food and Drug Administration (FDA) of […]

The post Juno Halts Clinical Trial of Leukemia Therapy for Second Time This Year appeared first on Immuno-Oncology News.


11/29/16, Immuno-Oncology News

Opinion: WHO?s Silence on Cannabis
Why the World Health Organization needs a radical rethink of its draconian approach to cannabis
11/29/16, The Scientist

NIAID-sponsored study to assess shorter-duration antibiotics in children
Trial will examine antibiotic use for community-acquired pneumonia.
11/28/16, National Institutes of Health

First new HIV vaccine efficacy study in seven years has begun
South Africa hosts historic NIH-supported clinical trial.
11/28/16, National Institutes of Health

T-cell Immunotherapy That Swaps Gene Parts Seen to Avoid Autoimmune Reaction in Mice

immunotherapy studyResearchers have found a way to engineer tumor-specific T-cell receptors (TCRs) that, when tested in mice as a cancer therapy, did not trigger autoimmune responses that can harm healthy cells. The finding may lead to safer cancer immunotherapies for patients. The study, “Domain-swapped T cell receptors improve the safety of TCR gene therapy,” was published in the journal eLife. […]

The post T-cell Immunotherapy That Swaps Gene Parts Seen to Avoid Autoimmune Reaction in Mice appeared first on Immuno-Oncology News.


11/28/16, Immuno-Oncology News

Pelican Newspaper: Gene profiling at Ocean Ridge Biosciences to unlock mysteries of the human body
Read More...
11/25/16, ORB Company News

A new strategic direction for behavioral and social sciences research at NIH
Strategic plan focuses on scientific priorities which reflect key research challenges that OBSSR is uniquely positioned to address.
11/23/16, National Institutes of Health

Targeting Myeloid Cells in Select Tumors May Strengthen Immune Checkpoint Inhibitors

immune defensesTargeting immunosuppressive myeloid cells within tumors with the PI3k-gamma inhibitor IPI-549 may be a way of preventing immune evasion by cytotoxic T-cells, according to a recent study published in Nature. The study, “Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells,” shows that such immunosuppressive cells are linked to immune checkpoint inhibitor resistance, suggesting that […]

The post Targeting Myeloid Cells in Select Tumors May Strengthen Immune Checkpoint Inhibitors appeared first on Immuno-Oncology News.


11/23/16, Immuno-Oncology News

Next Generation: Super-Fast Tracking of Single Molecules
A clever twist on a super-resolution microscopy technique improves the temporal resolution of single-molecule tracking. 
11/23/16, The Scientist

Genome Digest
What researchers are learning as they sequence, map, and decode species’ genomes
11/23/16, The Scientist

How Diet Influences Host-Microbiome Communication in Mice
Researchers are beginning to decipher the metabolic language of the microbiome, and determine how gut microbes communicate with host tissue.
11/23/16, The Scientist

Bacteria Show Signs of Starvation in Space
E. coli cultured on the International Space Station show increased expression of genes related to starvation and acid-resistance responses, researchers report.
11/18/16, The Scientist

Opinion: The Impact Factor, Re-envisioned
A combination of the traditional metric and the newer h5 index potentiates the scientific community toward more-balanced evaluation. 
11/18/16, The Scientist

How Epstein-Barr Virus Hijacks B Cells To Cause Blood Cancer
Scientists describe a mechanism by which EBV controls the expression of two genes, leading B cells to replicate out of control and avoid apoptosis.
11/18/16, The Scientist

Opinion: Repairing Peer Review
Peer review is in crisis, but should be fixed, not abolished.
11/18/16, The Scientist

Genetic Modification Improves Photosynthetic Efficiency
Researchers enhance the photosynthetic yield of tobacco plants with genetic engineering.
11/17/16, The Scientist

Opinion: Improving the Undergraduate Research Experience
Mentoring is critical for students just beginning to learn the ropes of biomedical research.
11/15/16, The Scientist

Researchers create synthetic cells to isolate genetic circuits
Encapsulating molecular components in artificial membranes offers more flexibility in designing circuits, report researchers.
11/14/16, ScienceDaily

Biologists give bacteria thermostat controls
A new helper in the fight against cancer and other diseases of the gut may be genetically altered bacteria that release medicines to tumors or the gut, report scientists.
11/14/16, ScienceDaily

NIH-led effort examines use of big data for infectious disease surveillance
Digital sources have the potential to provide more timely and detailed information on infectious disease threats or outbreaks.
11/14/16, National Institutes of Health

Advantages of Neanderthal DNA in the Human Genome
The retention of ancient hominin DNA in modern human genomes may have helped our ancestors adapt to life in diverse environments. 
11/10/16, The Scientist

People who know about genetically modified food agree with science: They're safe
People who know about genetically modified food agree with science, that they're safe. On the other hand, those who know plenty about global warming are cautious about the science that says humans cause the phenomenon, a new study shows. Furthermore, the study showed some people still make what researchers call "illusionary correlations," such as "genetically modified foods cause autism."
11/09/16, ScienceDaily

Model predicts elimination of GMO crops would cause hike in greenhouse gas emissions
A global ban on genetically modified crops would raise food prices and add the equivalent of nearly a billion tons of carbon dioxide to the atmosphere, a study shows.
11/08/16, ScienceDaily

Opinion: Assessing Frans de Waal?s Assessment of Animal Intelligence
In his latest book, the famed primatologist replaces one dogma with another.
11/08/16, The Scientist

Changing cell behavior could boost biofuels, medicine
A computer scientist has developed a way to coax cells to do natural things under unnatural circumstances, which could be useful for stem cell research, gene therapy and biofuel production. A research team has designed an algorithm, called NetSurgeon, that recommends genes to surgically remove from a cell’s genome to force it to perform a normal activity in a different environment or circumstance.
11/07/16, ScienceDaily

Corals Show Genetic Plasticity
Inshore corals thrive in a chaotic ecosystem thanks to dynamic gene-expression regulation, which may help the marine invertebrates better adapt to rising sea surface temperatures.
11/07/16, The Scientist

Palm Beach Post: ORB Leaves Palm Beach County for New Lab Space
Read More...
11/07/16, ORB Company News

Predicting Scientific Success
A scientist’s most influential paper may come at any point in her career but chances are it won’t change her overall success, researchers show.
11/03/16, The Scientist

Smoking-Linked Cancer Mutations Mapped
Scientists produce a detailed genomic map of mutations and epigenetic changes associated with smoking tobacco across 17 tumor types. 
11/03/16, The Scientist

Electron Micrographs Get a Dash of Color
A new technique creates colorful stains that label proteins and cellular structures at higher resolution than ever before possible. 
11/03/16, The Scientist

Chemists create clusters of organelles by mimicking nature
Scientists have succeeded in organizing spherical compartments into clusters mimicking the way natural organelles would create complex structures. They managed to connect the synthetic compartments by creating bridges made of DNA between them. This represents an important step towards the realization of so-called molecular factories.
11/02/16, ScienceDaily

How These Rodents Got Their Stripes
The African striped mouse and the chipmunk develop dorsal stripes through a newly identified mechanism of coat color variation.
11/02/16, The Scientist

Scientists flip molecular switches to distinguish closely related immune cell populations
The cornerstone of genetics is the loss-of-function experiment. In short, this means that to figure out what exactly gene X is doing in a tissue of interest—be it developing brain cells or a pancreatic tumor—you somehow cut out, switch off or otherwise destroy gene X in that tissue and then watch what happens. That genetic litmus test has been applied since before people even knew the chemical DNA is what makes up genes. What has changed radically are the tools used by biologists to inactivate a gene.
11/01/16, ScienceDaily

How Experience Shapes Adult Neurogenesis
Interneurons and mature granule cells in the adult mouse brain are critical for newborn neurons’ responses to novel environments.
10/27/16, The Scientist

NIH researchers unveil new wound-healing role for protein-folding gene in mice
Bethesda, Md., Thur., October 27, 2016 - National Institutes of Health researchers have identified a novel role for a gene known as heat shock protein 60 (Hsp60), finding that it is critical in tissue regeneration and wound healing. Researchers found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model. The study was published online today, October 27, in the journal npj Regenerative Medicine.


10/27/16, National Human Genome Research Institute

HIV Spread from Haiti to NYC in 1970, ?Patient Zero? Not to Blame
Whole-genome sequencing of preserved blood samples provides the clearest picture to date of the virus’s arrival and spread in the U.S.
10/26/16, The Scientist

DNA as an Artistic Medium
An artist creates images on electrophoresis gels using exhibition visitors’ pooled genetic material.
10/26/16, The Scientist

Added Neurons Are Functionally Integrated into Mouse Brain Circuits
In vivo imaging reveals how grafted embryonic brain cells grow, connect, and mature into contributing members of damaged visual pathways in adult mice.
10/26/16, The Scientist

Gene therapy shows promise for treating Niemann-Pick disease type C1�
Bethesda, Md., Wed., October 26, 2016 - or the first time, National Institutes of Health (NIH) researchers have demonstrated in mice that gene therapy may be the best method for correcting the single faulty gene that causes Niemann-Pick disease, type C1 (NPC1). The gene therapy involved inserting a functional copy of the NPC1 gene into mice with the disease; the treated animals were then found to have less severe NPC1 symptoms. The study, led by researchers at NIH's National Human Genome Research Institute (NHGRI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, was published Oct. 26, 2016, in the journal Human Molecular Genetics.


10/26/16, National Human Genome Research Institute

Celebration to Commemorate Ocean Ridge Biosciences Re-Opening at New Facility
Friday, November 18th, 2016 from 5:00PM to 8:00PM at 394 SW 12th Avenue, Deerfield Beach, FL.
Full Press Release...

10/25/16, ORB Company News

Double Take: Science-Inspired Art
An ongoing exhibition at Pace University in New York City features paintings and sculptures that relate to math, physics, and biology.
10/24/16, The Scientist

Culprit for Antibody Blockade Identified
Type I interferon organizes several immune mechanisms to suppress B cell responses to a chronic viral infection.
10/21/16, The Scientist

Tobacco plants engineered to manufacture high yields of malaria drug
In 2015, the Nobel Prize in Physiology or Medicine was awarded in part for the discovery of artemisinin, a plant-derived compound that's proven to be a lifesaver in treating malaria. Yet many people who need the drug are not able to access it, in part because it's difficult to grow the plant that is the compound's source. Now, research has shown that tobacco plants can be engineered to manufacture the drug at therapeutic levels.
10/20/16, ScienceDaily

PubPeer Requests that Court Consider Misconduct Investigation
ACLU lawyers representing the post-publication peer review site have filed a motion to admit the existence of a university investigation that found pathologist Fazlul Sarkar guilty of misconduct.
10/20/16, The Scientist

Many Evolutionary Paths Lead to Same Bird Trait
Diverse genetic changes lead to remarkably similar hemoglobin adaptations of diverse bird species, a study finds. 
10/20/16, The Scientist

Misconduct Finding Could Impact PubPeer Litigation
Wayne State University’s conclusion that pathologist Fazlul Sarkar committed research misconduct could affect the ongoing legal proceedings related to anonymous critics of his work.
10/19/16, The Scientist

Nixing NETs to Prevent Metastasis
Researchers discover that neutrophil extracellular traps help cancers spread, and design enzyme-loaded nanoparticles to destroy them.
10/19/16, The Scientist

Investigation Finds Pathologist Guilty of Systemic Misconduct
A Wayne State University probe into allegations of research misconduct leveled against pathologist Fazlul Sarkar has found the scientist guilty of multiple instances of image manipulation, among other infractions.
10/19/16, The Scientist

Genome Digest
What researchers are learning as they sequence, map, and decode species’ genomes
10/19/16, The Scientist

From Stem Cell to Oocyte In a Dish
For the first time, scientists generate functional mouse eggs from stem cells in culture.
10/17/16, The Scientist

Antifungal RNA spray could help fight barley crop disease
Spraying barley crops with RNA molecules that inhibit fungus growth could help protect the plants against disease, according to a new study. Plant diseases caused by fungi that grow on crops seriously threaten the world's food supply, and fungi can develop resistance to traditional pesticides.
10/13/16, ScienceDaily

Opinion: Stop Submitting Papers
This is not sustainable.
10/13/16, The Scientist

Deep-Sea Viruses Destroy Archaea
Viruses are responsible for the majority of archaea deaths on the deep ocean floors, scientists show.
10/12/16, The Scientist

Who Is Immune to Zika?
Researchers tap into ongoing dengue studies to improve antibody-based diagnostic tests for Zika and address unanswered questions about the emerging virus’s epidemiology.
10/11/16, The Scientist

Nascent Neurons Journey Through Newborn Brain
Young cells make their way to the frontal lobe to create new circuits in the brains of infants, researchers report. 
10/06/16, The Scientist

Opinion: Toot Your Horn
Why (and how) scientists should advocate for their research with journalists and policymakers
10/06/16, The Scientist

Michigan State Court of Appeals Hears Arguments in PubPeer Litigation
Attorneys representing pathologist Fazlul Sarkar and users of the post-publication peer review website present their cases regarding the constitutionality of subpoenaing for the identities of anonymous commenters.
10/05/16, The Scientist

Molecular Machinists Win Nobel
Chemists Jean-Pierre Sauvage, J. Fraser Stoddart, and Bernard Feringa are honored for their design and synthesis of molecular machines.
10/05/16, The Scientist

Researchers modify yeast to show how plants respond to a key hormone
Researchers have developed a novel toolkit based on modified yeast cells to tease out how plant genes and proteins respond to auxin, the most ubiquitous plant hormone. Their system allowed them to decode auxin's basic effects on a diverse family of plant genes.
09/27/16, ScienceDaily

New switch decides between genome repair, death of cells
The genetic information of every cell is encoded in the sequence of the DNA double helix. Double strand breaks in the DNA, which can be induced by radiation, are a dangerous threat to the cells, and if not properly repaired can lead to cancer. Damaged cells need to decide whether the breaks can be fixed or whether they should be removed by a cellular suicide program called “apoptosis” before initiating cancer.
09/27/16, ScienceDaily

Shedding light on the limits of the expanded genetic code
In 2014, scientists made a huge news splash when they reported the ability to grow bacteria with an expanded genetic code. Critics feared the rise of unnatural creatures; others appreciated the therapeutic potential of the development. Now, researchers have found that the expanded code might have an unforeseen limitation. A study reports that these novel components can damage cells when they are exposed to light.
09/15/16, ScienceDaily

Researcher calls for animal-human embryo research to proceed, but with strong animal protections
A researcher calls for animal-human embryo research to proceed – but only with strong animal protections in place. So-called "chimera" research raises the hope of producing human organs in genetically modified large animals, such as pigs and sheep, offering a potential solution to the persistent shortage of human organs for transplantation.
09/14/16, ScienceDaily

Breakthrough in genetic modification of grains
Genetic modification of plants might be controversial in commercial applications, but it is undeniably useful for research purposes. Despite years of effort, it has been remarkably difficult to develop efficient methods for transformation of grain crops. New work reports on a method to genetically modify maize and other grains.
09/12/16, ScienceDaily

Study reveals how ionising radiation damages DNA and causes cancer

For the first time, researchers from the Wellcome Trust Sanger Institute and their collaborators have been able to identify in human cancers two characteristic patterns of DNA damage caused by ionising radiation. These fingerprint patterns may now enable doctors to identify which tumours have been caused by radiation, and investigate if they should be treated differently.


09/12/16, BiologyNews.net

Human kidney progenitors isolated, offering new clues to cell renewal

In a first-of-its-kind look at human kidney development, researchers at The Saban Research Institute of Children's Hospital Los Angeles have isolated human nephron progenitor (NP) cells. Their results, published online in the journal Stem Cell Translational Medicine, will help scientists understand how these progenitor cells become renal cells in the developing fetus, and possibly offer a future way to foster renal regeneration after chronic kidney failure or acute injury.


09/12/16, BiologyNews.net

Protein found that initiates DNA repair
A research team has discovered a protein that may serve as a first responder that sets in motion a cascade of molecular activity to repair damaged DNA.
09/09/16, ScienceDaily

Giraffes more speciose than expected

Scientists from the Senckenberg and the Giraffe Conservation Foundation have analysed the genetic relationships of all major populations of giraffe in the wild. The large study on the genetic makeup of giraffe, published today in Current Biology, shows that there are four distinct giraffe species. Until now, only one giraffe species had been recognized. The unexpected results are based on analyses using several nuclear marker genes of more than 100 animals. The new insights are set to improve protection efforts of these endangered animals in Africa.


09/09/16, BiologyNews.net

New 'Trojan horse' antibody strategy shows promise against all Ebola viruses

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus. Two antibodies developed with this strategy blocked the invasion of human cells by all five ebolaviruses, and one of them protected mice exposed to lethal doses of Ebola Zaire and Sudan, the two most dangerous. The team included scientists from Albert Einstein College of Medicine, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Integrated Biotherapeutics, Vanderbilt University Medical Center, and The Scripps Research Institute.


09/09/16, BiologyNews.net

Was a researcher just served a world first CRISPR meal?
For (probably) the first time ever, plants modified with the "genetic scissors" CRISPR-Cas9 has been cultivated, harvested and cooked. D professor in Plant Cell and Molecular Biology served pasta with "CRISPRy" vegetable fry to a radio reporter. Although the meal only fed two people, it was still the first step towards a future where science can better provide farmers and consumers across the world with healthy, beautiful and hardy plants.
09/05/16, ScienceDaily

Brain circuit that drives sleep-wake states, sleep-preparation behavior is identified

Stanford University School of Medicine scientists have identified a brain circuit that's indispensable to the sleep-wake cycle. This same circuit is also a key component of the reward system, an archipelago of interconnected brain clusters crucial to promoting behavior necessary for animals, including humans, to survive and reproduce.


09/05/16, BiologyNews.net

Biochemists' discovery could lead to vaccine against 'flesh-eating' bacteria

Biochemists at the University of California San Diego have uncovered patterns in the outer protein coat of group A Streptococcus that could finally lead to a vaccine against this highly infectious bacteria--responsible for more than 500,000 deaths a year, including toxic shock syndrome and necrotizing fasciitis or "flesh-eating disease."


09/05/16, BiologyNews.net

New genus of bacteria found living inside hydraulic fracturing wells


Ohio State University researchers and their colleagues have identified a new genus of bacteria living inside hydraulic fracturing wells.
Researchers analyzing the genomes of microorganisms living in shale oil and gas wells have found evidence of sustainable ecosystems taking hold there--populated in part by a never-before-seen genus of bacteria they have dubbed "Frackibacter."


09/05/16, BiologyNews.net

Forensic DNA analysis checks the origin of cultured cells
Cell lines are cultured cells that are commonly used in medical research. New results show that such cells are not always what they are assumed to be. Using genetic analyses, the researchers showed that a commonly used cell line that was established almost 50 years ago does not originate from the patient it is claimed to stem from.
08/31/16, ScienceDaily

More tomatoes, faster: Accelerating tomato engineering
While looking for ways to make tomatoes and other crop plants more productive, researchers developed a way to cut the time required to modify a tomato's genes by six weeks. The improvement will save on money and resources while accelerating tomato research.
08/30/16, ScienceDaily

More tomatoes, faster: Accelerating tomato engineering


A researcher transfers tomato plantlets from a plate of regeneration medium.
Tomatoes are already an ideal model species for plant research, but scientists at the Boyce Thompson Institute (BTI) just made them even more useful by cutting the time required to modify their genes by six weeks.


08/30/16, BiologyNews.net

New species of pterosaur discovered in Patagonia


This is a paleoartist's reconstruction of a ptesosaur.
Scientists today announced the discovery of a new species of pterosaur from the Patagonia region of South America. The cranial remains were in an excellent state of preservation and belonged to a new species of pterosaur from the Early Jurassic. The researchers have named this new species 'Allkauren koi' from the native Tehuelche word 'all' for 'brain', and 'karuen' for 'ancient'.


08/30/16, BiologyNews.net

Study finds shark fins & meat contain high levels of neurotoxins linked to Alzheimer's disease


Cyanobacterial neurotoxin β-N-methylamino-L-alanine (BMAA) and Mercury are detected in sharks from the Atlantic and Pacific Oceans.
In a new study, University of Miami (UM) scientists found high concentrations of toxins linked to neurodegenerative diseases in the fins and muscles of 10 species of sharks. The research team suggests that restricting consumption of sharks can have positive health benefits for consumers and for shark conservation, since several of the sharks analyzed in the study are threatened with extinction due to overfishing.


08/29/16, BiologyNews.net

Artificial intelligence expedites breast cancer risk prediction

Researchers at Houston Methodist have developed an artificial intelligence (AI) software that reliably interprets mammograms, assisting doctors with a quick and accurate prediction of breast cancer risk. According to a new study published in Cancer (early online Aug. 29), the computer software intuitively translates patient charts into diagnostic information at 30 times human speed and with 99 percent accuracy.


08/29/16, BiologyNews.net

Purest yet liver-like cells generated from induced pluripotent stem cells


This image shows induced pluripotent stem cells expressing a characteristic cell surface protein called SSEA4 (green).
A research team including developmental biologist Stephen A. Duncan, D. Phil., SmartStateTM Chair of Regenerative Medicine at the Medical University of South Carolina (MUSC), has found a better way to purify liver cells made from induced pluripotent stem cells (iPSCs). Their efforts, published August 25, 2016 in Stem Cell Reports, will aid studies of liver disease for the National Heart, Lung, and Blood Institute (NHLBI)'s $80 million Next Generation Genetic Association Studies (Next Gen) Program. The University of Minnesota (Minneapolis) and the Medical College of Wisconsin (Milwaukee) contributed to the study.


08/29/16, BiologyNews.net

Yale team discovers how Zika virus causes fetal brain damage

Infection by the Zika virus diverts a key protein necessary for neural cell division in the developing human fetus, thereby causing the birth defect microcephaly, a team of Yale scientists reported Aug. 24 in the journal Cell Reports.


08/25/16, BiologyNews.net

In some genetic cases of microcephaly, stem cells fail to launch

In a very severe, genetic form of microcephaly, stem cells in the brain fail to divide, according to a new Columbia University Medical Center study that may provide important clues to understanding how the Zika virus affects the developing brain.


08/25/16, BiologyNews.net

NIH researchers discover otulipenia, a new inflammatory disease
Bethesda, Md., Mon., August 22, 2016 -�National Institutes of Health researchers have discovered a rare and sometimes lethal inflammatory disease - otulipenia - that primarily affects young children. It is caused by the malfunction of OTULIN, a single gene on chromosome 5. They also identified anti-inflammatory treatments to ease some of the patients' symptoms: fever, skin rashes, diarrhea, joint pain and overall failure to grow or thrive. Read more in the Aug. 22, early edition of the Proceedings of the National Academy of Sciences.


08/22/16, National Human Genome Research Institute

Synthetic biology: Engineering a chemical switch into a light-driven proton pump
Synthetic biology is an emerging and rapidly evolving engineering discipline. Now scientists have engineered a chemically switchable version of the light-driven proton pump proteorhodopsin -- an essential tool for efficiently powering molecular factories and synthetic cells.
08/09/16, ScienceDaily

Scientists program cells to remember and respond to series of stimuli
Engineers have programmed cells to remember and respond to events. This approach to circuit design enables scientists to create complex cellular state machines and track cell histories.
07/21/16, ScienceDaily

Synthetic biology used to limit bacterial growth and coordinate drug release
Researchers have engineered a clinically relevant bacterium to produce cancer drugs and then self-destruct and release the drugs at the site of tumors. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The strategy represents the use of synthetic biology in therapeutics.
07/20/16, ScienceDaily

Malaria: A genetically attenuated parasite induces an immune response
With nearly 3.2 billion people currently at risk of contracting malaria, scientists have experimentally developed a live, genetically attenuated vaccine for Plasmodium, the parasite responsible for the disease. By identifying and deleting one of the parasite's genes, the scientists enabled it to induce an effective, long-lasting immune response in a mouse model. These findings were published in the Journal of Experimental Medicine on July 18, 2016.
07/18/16, ScienceDaily

Gas sensors 'see' through soil to analyze microbial interactions
Researchers use programmed bacteria as gas sensors that help them 'see' into soil to learn about the behavior of the microbial communities within.
07/18/16, ScienceDaily

Proteins team up to turn on T cells
Scientists are learning how cells make the decision to become T cells.
07/15/16, ScienceDaily

Stem cells feel the force
Scientists have gained new insights into how stem cells feel and respond to external mechanical forces by changing the way DNA is organized in the nucleus, and thereby the expression of genes that are required for stem cell differentiation.
07/12/16, ScienceDaily

Researchers advance treatment possibilities for Gaucher, Parkinson's
Bethesda, Md., Mon., July 12, 2016 - NIH researchers have identified and tested a molecule that shows promise as a possible treatment for the rare Gaucher disease and the more common Parkinson's disease. These findings demonstrate how insights from a rare disorder can have direct relevance to the treatment of more common disorders. The findings were published July 12, 2016 in The Journal of Neuroscience.


07/12/16, National Human Genome Research Institute

<em>Media Availability</em>: Genetics of type 2 diabetes revealed in unprecedented detail
Bethesda, Md., Mon., July 11, 2016 - A comprehensive investigation of the underlying genetic architecture of type 2 diabetes has unveiled the most detailed look at the genetic differences that increase a person's risk for disease development. The findings, published July 11 in the journal Nature, reveal the complexity of the disease in more detail than previously appreciated and also identify several promising targets for new treatments.


07/11/16, National Human Genome Research Institute

Researchers harness DNA as the engine of super-efficient nanomachine
Researchers have established a way to harness DNA as the engine of a microscopic 'machine' they can turn on to detect trace amounts of substances that range from viruses and bacteria to cocaine and metals.
07/07/16, ScienceDaily

E. coli: The ideal transport vehicle for next-gen vaccines?
Researchers have developed an E. coli-based transport capsule designed to help next-generation vaccines do a more efficient and effective job than today's immunizations. The research highlights the capsule's success fighting pneumococcal disease, an infection that can result in pneumonia, sepsis, ear infections and meningitis.
07/01/16, ScienceDaily

Individual mycobacteria respond differently to antibiotics based on growth and timing
Scientists have identified factors that linked to why individual mycobacteria of the same genetic background can respond differently to antibiotics. The findings shed light on the complexity of antibiotic tolerance and may improve the future design of drug regimens.
07/01/16, ScienceDaily

Unsilencing silenced genes by CRISPR/Cas9
Scientists have developed a new technique to unleash silenced genes and change cell fates using CRISPR/Cas9.
07/01/16, ScienceDaily

Fix for 3-billion-year-old genetic error could dramatically improve genetic sequencing
Researchers found a fix for a 3-billion-year-old glitch in one of the major carriers of information needed for life, RNA, which until now produced errors when making copies of genetic information. The discovery will increase precision in genetic research and could dramatically improve medicine based on a person's genetic makeup.
06/23/16, ScienceDaily

A new bio-ink for 3-D printing with stem cells
Scientists have developed a new kind of bio-ink, which could eventually allow the production of complex tissues for surgical implants. The new stem cell-containing bio ink allows 3-D printing of living tissue, known as bio-printing.
06/23/16, ScienceDaily

Virus uses 'stolen' CRISPR to hack its host's immune system
Microbiologists have discovered that the Cyanophage N1 virus carries a DNA sequence -- a CRISPR -- that is generally used by bacteria to fight off viral infection. The virus appears to use the stolen bits of immune system DNA to highjack their hosts' immune response.
06/14/16, ScienceDaily

Gene-drive modified organisms are not ready to be released into environment, experts say
The emerging science of gene drives has the potential to address environmental and public health challenges, but gene-drive modified organisms are not ready to be released into the environment and require more research in laboratories and highly controlled field trials, says a new report.
06/08/16, ScienceDaily

Gene circuits in live cells can perform complex computations
Researchers have developed a technique to integrate both analogue and digital computation in living cells, allowing them to form gene circuits capable of carrying out complex processing operations.
06/03/16, ScienceDaily

Genetically modified golden rice falls short on lifesaving promises
Heralded on the cover of Time magazine in 2000 as a genetically modified (GMO) crop with the potential to save millions of lives in the Third World, Golden Rice is still years away from field introduction and even then, may fall short of lofty health benefits still cited regularly by GMO advocates, suggests a new study.
06/03/16, ScienceDaily

New CRISPR system for targeting RNA
Researchers have characterized a new CRISPR system that targets RNA, rather than DNA. The new approach has the potential to open a powerful avenue in cellular manipulation.
06/02/16, ScienceDaily

New 'genetic barcode' technique reveals details of cell lineage
By using the gene editing tool CRISPR to create unique genetic 'barcodes,' it's possible to track the lineage of cells in a living organism, a new study reveals.
05/26/16, ScienceDaily

Consumer knowledge gap on genetically modified food
While consumers are aware of genetically modified crops and food, their knowledge level is limited and often at odds with the facts, according to a newly published study.
05/25/16, ScienceDaily

New tools to manipulate biology
Chemistry has provided many key tools and techniques to the biological community in the last twenty years. We can now make proteins that Mother Nature never thought of, image unique parts of live cells and even see cells in live animals. Biologists now take these accomplishments a step further, reporting advances in both how proteins are made and how you can see their expression patterns in live animals.
05/24/16, ScienceDaily

A path away from reliance on oil, with the help of bacteria
Adding genes to bacteria offers sustainable routes to make compounds currently obtained from petrochemicals.
05/19/16, ScienceDaily

Biologists find how plants reconstitute stem cells
Stem cells are typically thought to have the intrinsic ability to generate or replace specialized cells. However, a team of biologists has shown that regenerating plants can naturally reconstitute their stem cells from more mature cells by replaying embryogenesis.
05/19/16, ScienceDaily

Genetically engineered crops: Experiences and prospects
An extensive study has found that new technologies in genetic engineering and conventional breeding are blurring the once clear distinctions between these two crop-improvement approaches.
05/17/16, ScienceDaily

Chance finding could transform plant production
An almost entirely accidental discovery by researchers could transform food and biofuel production and increase carbon capture on farmland. By tweaking a plant’s genetic profile, the researchers doubled the plant’s growth and increased seed production by more than 400 per cent.
05/17/16, ScienceDaily

NIH funds new studies on ethical, legal and social impact of genomic information
Bethesda, Md., Tues., May 17, 2016 - Four new grants from the National Institutes of Health will support research on the ethical, legal and social questions raised by advances in genomics research and the increasing availability of genomic information. The awards will fund researchers at interdisciplinary centers through the National Human Genome Research Institute's (NHGRI) Centers of Excellence in Ethical, Legal and Social Implications Research (CEER) program.


05/17/16, National Human Genome Research Institute

Photosynthetic bacteria give biologists a cool new tool
Bioengineers have converted a protein pathway found in freshwater photosynthetic bacteria into the first engineered transcriptional regulatory tool that is activated exclusively by UV-violet light. The tool could make the manufacture of drugs and other substances by engineered bacteria more efficient.
05/10/16, ScienceDaily

NIH creates Atlas of Human Malformation Syndromes in Diverse Populations
Researchers with the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, have collaborated with physicians and medical geneticists around the world to create the Atlas of Human Malformation Syndromes in Diverse Populations. Health care providers can use the new atlas to diagnose diverse patients with inherited diseases by comparing physical traits (called phenotypes) and written descriptions of their symptoms with photos and descriptions of people with the same condition and ancestry. Previously, the only available diagnostic atlas featured photos of patients with northern European ancestry, which often does not represent the characteristics of these diseases in patients from other parts of the world. The free electronic atlas was announced online in Genetics in Medicine.


04/29/16, National Human Genome Research Institute

Media Availability: NHGRI celebrates National DNA Day with events that promote genomic literacy
The National Human Genome Research Institute (NHGRI) will celebrate its fourteenth annual National DNA Day on Monday, April 25, 2016. National DNA Day commemorates the successful completion of the Human Genome Project in 2003 and the discovery of DNA's double helix in 1953. NHGRI, part of the National Institutes of Health (NIH), began celebrating this day annually on April 25, 2003, after the 108th Congress passed concurrent resolutions designating it as "National DNA Day." To mark this historic day, NHGRI is hosting events in the week leading up to and on National DNA Day.


04/11/16, National Human Genome Research Institute

'Honeycomb' of nanotubes could boost genetic engineering
Researchers have developed a new and highly efficient method for gene transfer. The technique, which involves culturing and transfecting cells with genetic material on an array of carbon nanotubes, appears to overcome the limitations of other gene editing technologies.
04/06/16, ScienceDaily

Pros and cons of mandatory GMO labeling
Researchers have concluded that mandatory labeling of genetically modified foods is justified, based on an extensive review of international scientific and legal frameworks related to genetically modified organisms (GMOs).
04/01/16, ScienceDaily

Proving the genetic code's flexibility
Three-letter codons in a genome sequence can represent one of the 20 regularly used amino acids or stops. Scientists have discovered that microorganisms recognize more than one codon for selenocysteine. The finding adds credence to recent studies indicating that an organism's genetic vocabulary is not as constrained as had been long held.
03/31/16, ScienceDaily

New tools allow rapid ID of CRISPR-Cas system PAMs
CRISPR-Cas systems are widely heralded as a new generation of genetic tools. But development of these tools requires researchers to identify the protospacer-adjacent motifs that unlock each system's functionality. A new set of techniques expedites PAM identification -- and early testing finds that many CRISPR-Cas systems actually have multiple PAMs of varying strength.
03/31/16, ScienceDaily

New methods of enhancing efficiency of genetic engineering in mice, rats
Two new gene modification methods have been developed: lsODN (long single-stranded oligodeoxynucleotide) and 2H2OP (two-hit two-oligo with plasmid). These methods use CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) -Cas systems and ssODN (single-stranded oligodeoxynucleotide).
03/24/16, ScienceDaily

For first time, scientists use CRISPR-Cas9 to target RNA in live cells
Scientists have long sought an efficient method for targeting RNA -- intermediary genetic material that carries the genetic code from the cell's nucleus to protein-making machinery -- in living cells. Researchers have now achieved this by applying the popular DNA-editing technique CRISPR-Cas9 to RNA.
03/17/16, ScienceDaily

Unlocking the secrets of squid sucker ring teeth
A squid has more in common with a spider than you may think. The razor-sharp 'teeth' that ring the suckers found on some squid tentacles are made up entirely of proteins remarkably similar -- and in some ways superior -- to the ones found in silks. Those proteins, called suckerins, give the teeth their strength and stretchiness, and could one day be used as the basis for biomaterials with many potential biomedical applications.
03/01/16, ScienceDaily

Engineered swarmbots rely on peers for survival
Researchers have engineered microbes that can't run away from home. Any refugees that do quickly die without protective proteins produced by their peers. Dubbed 'swarmbots' for their ability to survive in a crowd, the system could be used as a safeguard to stop genetically modified organisms from escaping into the surrounding environment. It could also reliably program colonies of bacteria to respond to changes in their surrounding environment.
02/29/16, ScienceDaily

Bacteria take 'RNA mug shots' of threatening viruses
Scientists have discovered that bacteria have a system that can recognize and disrupt dangerous viruses using a newly identified mechanism involving RNA. It is similar to the CRISPR/Cas system that captures foreign DNA. The discovery might lead to better ways to thwart viruses that kill agricultural crops and interfere with the production of dairy products such as cheese and yogurt.
02/25/16, ScienceDaily

Genetically modified E. coli pump out morphine precursor
Bioengineers have tweaked Escherichia coli genes so that they pump out thebaine, a morphine precursor that can be modified to make painkillers. The genetically modified E. coli produces 300 times more thebaine with minimal risk of unregulated use compared to a recently developed method involving yeast.
02/25/16, ScienceDaily

EU decision process hinders use of genetically modified trees
Just like other crops, trees can also be genetically modified in order to introduce new, useful characteristics. Although such trees offer many socio-economic and environmental benefits, complex and unpredictable EU procedures are hindering their introduction to the market. This is the conclusion reached by researchers in a joint text drawn up as part of a European Cooperation in Science and Technology (COST) project about genetically modified trees. The researchers state that Europe is lagging behind in worldwide GM developments and call for a more scientifically substantiated decision process.
02/24/16, ScienceDaily

Microbiologists advance CRISPR research
Scientists have known for years that bacteria have the ability to fight off invading viruses but considered their immune systems to be relatively primitive. However, a new discovery in recent years of CRISPRs, an acronym for "clustered regularly-interspaced short palindromic repeats," changed that perception.
02/22/16, ScienceDaily

New device may speed up DNA insertion into bacteria
A new microfluidic device may help scientists quickly home in on the electric field 'sweet spot' -- the range of electric potentials that will harmlessly and temporarily open up membrane pores to let DNA in. In principle, the simple device could be used on any microorganism or cell, significantly speeding up the first step in genetic engineering.
02/19/16, ScienceDaily

NIH researchers identify striking genomic signature shared by five types of cancer
National Institutes of Health researchers have identified a signature in tumor DNA that occurs in five different types of cancer. They also found evidence that this methylation signature may be present in many more types of cancer. The specific signature results from a chemical modification of DNA called methylation, which can control the expression of genes like a dimmer on a light switch. Researchers hope to spur development of a blood test that can be used to diagnose a variety of cancers at early stages. The study appears today, February 5, 2016, in The Journal of Molecular Diagnostics.


02/05/16, National Human Genome Research Institute

NIH Scientists Discover Genetic Cause of Rare Allergy to Vibration
Scientists at the National Institutes of Health (NIH) and the National Human Genome Research Institute have identified a genetic mutation responsible for a rare form of inherited hives induced by vibration, also known as vibratory urticaria. Running, hand clapping, towel drying or even taking a bumpy bus ride can cause temporary skin rashes in people with this rare disorder.


02/03/16, National Human Genome Research Institute

NIH genome sequencing program targets the genomic bases of common, rare disease
The National Institutes of Health will fund a set of genome sequencing and analysis centers whose research will focus on understanding the genomic bases of common and rare human diseases. The National Human Genome Research Institute (NHGRI), part of NIH, today launched the Centers for Common Disease Genomics (CCDG), which will use genome sequencing to explore the genomic contributions to common diseases such as heart disease, diabetes, stroke and autism. NHGRI also announced the next phase of a complementary program, the Centers for Mendelian Genomics (CMG), which will continue investigating the genomic underpinnings of rare, typically inherited diseases, such as cystic fibrosis and muscular dystrophy.


01/14/16, National Human Genome Research Institute

Individualized Medicine at Ocean Ridge Biosciences featured in The Palm Beach Post
Individualized Medicine at Ocean Ridge Biosciences featured in The Palm Beach Post...
06/17/15, ORB Company News

Identification of Circulating Biomarkers in Patients with Active Inflammatory Bowel Disease
ORB Contributes to New Findings in Inflammatory Bowel Disease Research Implications for the Development of a Non-Invasive Diagnostic Panel
Full Press Release...

03/09/15, ORB Company News

ORB Contributes to New Study Examining the RNA Content of Human Seminal Exosomes
Ocean Ridge Biosciences (ORB) is pleased to announce its contribution to a recent publication in volume 42 issue 11 of Nucleic Acids Research, entitled “Exosomes in human semen carry a distinctive repertoire of small non-coding RNAs with potential regulatory functions”. The article reveals potential mechanisms by which semen interferes with immune responses in the recipient fem...
07/23/14, ORB Company News

Ocean Ridge Contributes to Discovery of Biomarkers of Early-Stage Pancreatic Cancer
Ocean Ridge Biosciences is honored to announce its contribution to a landmark study to discover biomarkers of early-stage pancreatic cancer....
03/18/14, ORB Company News

ORB Contributes to Recently Published Study on Mechanisms of Aortic Valve Calcification
Ocean Ridge Biosciences (ORB) is honored to announce its contribution to a recently published, well respected publication titled, "Increased Dietary Intake of Vitamin A Promotes Aortic Valve Calcification In Vivo". ...
04/01/13, ORB Company News

Toxikon Forms Partnership with Ocean Ridge Biosciences
Preclinical CRO will globally market services and capabilities together with genomics services provider for development novel drugs and medical devices...
10/26/11, ORB Company News

ORB awarded grant for development of prognostic biomarkers of Emphysema
Ocean Ridge Biosciences, LLC (ORB) today announced that it has been awarded a $69,435 grant under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act....
11/02/10, ORB Company News

Contact Us

Ocean Ridge Biosciences, LLC
394 SW 12th Ave
Deerfield Beach, Florida 33442
Phone: 754-600-5128
Fax: 561-427-7845
Email: array@oceanridgebio.com